Abstract Result Announcement

Thank you very much for submitting your abstract(s) to the 20th Conference of the APASL. All submitted abstracts have been evaluated and below are the final result.

Instructions to Presenting Authors of Accepted Abstracts

For Oral Presentations:

For Poster Presentations/Exhibitions:

All presenting authors of accepted abstracts will enjoy a special registration fee at RMB 1,000 for pre-registration on or before 4 January 2010 or RMB 1,400 for onsite registration. Click here to start registration!

Oral Presentations

Poster Presentations

 

Oral Presentations

Plenary Presentation 1
Date: 26 March 2010 (Friday)
Venue: Function Room A
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-01 SA01277 11:30 - 11:45 Zhong-Qi Bian siRNA  Targeting HBV Gene Inhibits Hepatitis B Virus Expression and Replication in BHK-21 Cells
top
Plenary Presentation 2
Date: 26 March 2010 (Friday)
Venue: Function Room B
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL02 SA01627 11:30 - 11:45 Zhi-Ling Yu ERp57 is overexpressed in an in vitro hepatosteatosis model and livers of patients with nonalcoholic fatty liver disease
top
Plenary Presentation 3
Date: 26 March 2010 (Friday)
Venue: Function Room C
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-03 SA00402 11:30 - 11:45 Ed Gane Treatment of recurrent hepatitis C following liver transplantation – the essential role of ribavirin
top
Plenary Presentation 4
Date: 26 March 2010 (Friday)
Venue: Function Room A
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-04 SA00968 15:30 - 15:45 Rong-Nan Chien Decline of Hepatitis B Virus Surface Antigen Levels Correlated with Sustained HBeAg Response during Lamivudine Plus Thymosin alpha-1 Combined Therapy of Chronic Hepatitis B
top
Plenary Presentation 5
Date: 26 March 2010 (Friday)
Venue: Function Room B
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-05 SA00764 15:30 - 15:45 Xiaoning Wu HBV Promotes Collagen Type I Expression through P38MAPK Pathway in Human Hepatic Stellate Cell Line, LX-2 Cell
top
Plenary Presentation 6
Date: 26 March 2010 (Friday)
Venue: Function Room C
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-06 SA00159 15:30 - 15:45 Hidenori Toyoda Prognostic significance of a highly sensitive measurement of serum Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with normal alpha-fetoprotein
top
Plenary Presentation 7
Date: 27 March 2010 (Saturday)
Venue: Function Room A
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-07 SA01640 11:30 - 11:45 Gyongyi Szabo TLR7 Expression and Function is Decreased in HCV Infected Hepatoma Cells
top
Plenary Presentation 8
Date: 27 March 2010 (Saturday)
Venue: Function Room B
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-08 SA01633 11:30 - 11:45 Showkat Ali Zargar Wait-and-See Policy (Conservative Treatment) vs. Cholecystectomy after Endoscopic Sphincterotomy for Bile Duct Stones in Patients with co-existing Gallbladder Stones in Elderly and high Surgical Risk Patients: a Prospective Randomized Trial
top
Plenary Presentation 9
Date: 27 March 2010 (Saturday)
Venue: Function Room C
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-09 SA00186 11:30 - 11:45 Shozo Iwamoto Angio-CT findings of 115 small hepatocellular carcinomas of 61 patients during follow-up of 659 patients with chronic liver disease.Clinical features of early cancers
top
Plenary Presentation 10
Date: 27 March 2010 (Saturday)
Venue: Function Room A
Presentation No Submission No. Presentation Time Presenting Author Presentation Title
PL-10 SA01728 15:30 - 15:45 Ana Carolina Cardoso METABOLIC FACTORS HAVE NO INFLUENCE ON ACCURACY OF TRANSIENT ELASTOGRAPHY IN CHRONIC HEPATITIS B AND C
top
Plenary Presentation 11
Date: 27 March 2010 (Saturday)
Venue: Function Room B
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-11 SA01428 15:30 - 15:45 Nitin Gupta Natural history of asymptomatic and symptomatic portal biliopathy in patients with extra-hepatic portal vein obstruction (EHPVO)
top
Plenary Presentation 12
Date: 27 March 2010 (Saturday)
Venue: Function Room C
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-12 SA01404 15:30 - 15:45 Kevin Ka Wan Chu Radiological Characteristics of Hepatocellular Carcinoma with Better Survivals after Partial Hepatectomy
top
Plenary Presentation 13
Date: 28 March 2010 (Sunday)
Venue: Function Room A
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-13 SA01065 11:30 - 11:45 De-Ming Tan Immunological mechanism responsible for non-response to hepatitis B virus vaccine in healthy adults
top
Plenary Presentation 14
Date: 28 March 2010 (Sunday)
Venue: Function Room B
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-14 SA01212 11:30 - 11:45 Ming Shi Safety and efficacy of human mesenchymal stem cells for treatment of HBV-associated liver failure
top
Plenary Presentation 15
Date: 28 March 2010 (Sunday)
Venue: Function Room C
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
PL-15 SA01397 11:30 - 11:45 Donald Poon A pilot experience of oxaliplatin/adriamycin/5 fluorouracil continuous infusion/interferon α-2b (OXAFI) in unresectable non-metastatic hepatocellular carcinoma (HCC).
top
Free Paper Presentation 1: Hepatitis B (I)
Date: 26 March 2010 (Friday)
Venue: Meeting Room 401
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-01 SA00632 16:15 - 16:25 Karsten Wursthorn Development Of A Protocol For The Quantitative Determination Of HBeAg Using The Elecsys® HBeAg Immunoassay
FP-02 SA01438 16:25 - 16:35 Jack Wallace Developing a national response: Putting the chronic into hepatitis B
FP-03 SA00244 16:35 - 16:45 Yue-qiu Gao Predominant frequency of mixture infection of genotypes B/C in patients with DNA-positive chronic hepatitis B in shanghai
FP-04 SA00302 16:45 - 16:55 Siddhartha Mishra Correlation of Early Viral Kinetics and Treatment Response During Tenofovir Treatment in Chronic Hepatitis B (CHB) Patients
FP-05 SA00421 16:55 - 17:05 Feng Liu Dynamic changes of hepatitis B virus quasispecies during early entecavir treatment in patients with different responses
FP-06 SA00544 17:05 - 17:15 Xiaoyong Zhang Modulation of HBV Replication and hepatocytes differentiation by MicroRNA-1
FP-07 SA00838 17:15 - 17:25 Yanwei Zhong A novel method for quantitative detection of HBV cccDNA using rolling cycle amplification in combination with TaqMan real-time PCR
FP-08 SA00973 17:25 - 17:35 Xu Lin Expression of PD-1 on peripheral blood T cells during different immune status in patients with chronic hepatitis B
FP-09 SA01126 17:35 - 17:45 Mamun Mahtab Early Completion of Immune Clearance State of HBV Infection in Bangladesh: An Observation
FP-10 SA01443 17:45 - 17:55 Long Xu Immunotolerance in HBV-hydrodynamic injected adult mice
FP-11 SA01539 17:55 - 18:05 Wing I Cheung Prospective evaluation of occult hepatitis B viral (HBV) infection in lymphoma patients receiving chemotherapy
FP-12 SA01698 18:05 - 18:15 Jing You Variation in liver histopathology in chronic HBV-infected individuals with normal liver function tests correlates with HBV replication
top
Free Paper Presentation 2: Hepatitis B (II)
Date: 26 March 2010 (Friday)
Venue: Meeting Room 402
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-13 SA01512 16:15 - 16:25 Hwai-I Yang Development and Validation of a Predictive Risk Score for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
FP-14 SA00647 16:25 - 16:35 Andrew Vaillant PRELIMINARY EVIDENCE OF RAPID HBsAg SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH A DNA-BASED AMPHIPATHIC POLYMER
FP-15 SA00825 16:35 - 16:45 Shiyi Chen A dendritic cell-based therapeutic vaccine against chronic hepatitis B containing human-consumable hepatitis B surface antigen and core antigen in hepatitis B virus transgenic mice
FP-16 SA00785 16:45 - 16:55 Patrick Marcellin Long Term (3 Year) Efficacy, Safety and Resistance of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Positive and Negative Patients with Chronic Hepatitis B
FP-17 SA00851 16:55 - 17:05 Scott Bowden Hepatitis B Virus Multidrug Resistant rtA181(sW172/L173) Variants In Patients On Long Term Antiviral Therapy.
FP-18 SA00912 17:05 - 17:15 HB Lou Establishment of Immortalized Human B-cell Culture Secreting Anti-HBs
FP-19 SA01218 17:15 - 17:25 Ed Gane Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B, Preliminary Analysis
FP-20 SA01255 17:25 - 17:35 Sharon Lewin Factors associated with hepatotoxicity in an international HIV/HBV co-infected cohort on long-term HAART
FP-21 SA01239 17:35 - 17:45 Bang-Fu Wu Preliminary clinical study of anti-HBV-DC combine lamivudine and Thymosin-a1 treating the HBeAg positive chronic hepatitis B patients
FP-22 SA01421 17:45 - 17:55 Lin Zhuang Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels
FP-23 SA01777 17:55 - 18:05 Massimo Levrero OptiB - a multicenter prospective open label study on Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment:
FP-24 SA01380 18:05 - 18:15 Seng Gee Lim Reimbursement Policies In Asia-Pacific For Chronic Hepatitis B
top
Free Paper Presentation 3: Liver Fibrosis (I)
Date: 26 March 2010 (Friday)
Venue: Meeting Room 403
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-25 SA00474 16:15 - 16:25 Feng Liu Epithelial to mesenchymal transition contributes to liver fibrosis during chronic hepatitis B
FP-26 SA00587 16:25 - 16:35 Nermine Ehsan Immunohistochemical Expression of Hepatocyte Growth Factor Activator In Liver Biopsies of Egyptian Patients with Chronic Hepatitis of Various Etiologies: Correlation With Tissue Markers of Fibrosis
FP-27 SA00147 16:35 - 16:45 COSMAS RINALDI LESMANA Diagnostic accuracy of transient elastography versus aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: Preliminary data.
FP-28 SA00218 16:45 - 16:55 Grace LH Wong Development of a Non-invasive Algorithm with Transient Elastography (Fibroscan®) and Serum Test Formula for Advanced Liver Fibrosis in Chronic Hepatitis B
FP-29 SA00546 16:55 - 17:05 Daryl Crawford Mdr2 -/- mice have a distinct temporal pattern of fibrogenic activity: Potential anti-fibrotic therapy should be evaluated in different models and stages of the fibrogenic process.
FP-30 SA00571 17:05 - 17:15 Jinlin Hou Liver stiffness measured by transient elastography can predict liver fibrosis in Chinese patients with chronic hepatitis B
FP-31 SA00630 17:15 - 17:25 Chen-Hua Liu Transient Elastography for the Assessment of Hepatic Fibrosis in Hemodialysis Patients with Chronic Hepatitis C
FP-32 SA00691 17:25 - 17:35 Victor De Lédinghen Evolution of liver stiffness values in acute hepatitis: interim analysis of a prospective multicentre study
FP-33 SA00721 17:35 - 17:45 Yuguo Zhang Assessment of Hepatic Fibrosis by Transient Elastography in Patients With Chronic Hepatitis B
FP-34 SA01356 17:45 - 17:55 Jinsheng Guo DOMINANT-NEGATIVE EFFECT OF DDX5 S480A POLYMORPHISM ON ITS TRANSCRIPTIONAL REGULATION OF FIBROGENIC GENES IN HEPATIC STELLATE CELLS
FP-35 SA01599 17:55 - 18:05 Seung Up Kim What are "true normal" liver stiffness values using FibroScan®?: A prospective study in healthy living liver and kidney donors in South Korea
FP-36 SA01620 18:05 - 18:15 Hui Won Jang The usefulness of liver stiffness measurement using FibroScan® in patients with chronic hepatitis C in South Korea: a multicenter, prospective study
top
Free Paper Presentation 4: Liver Transplantation
Date: 26 March 2010 (Friday)
Venue: Meeting Room 405
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-37 SA00963 16:15 - 16:25 Thomas Decaens Impact of chemoembolization with doxorubicin loaded beads (DC beads) in patients awaiting liver transplantation for HCC.
FP-38 SA01141 16:25 - 16:35 Waleed Al-hamoudi Pegylated Interferon Alfa-2a and Ribavirin For The Treatment Of Genotype-4 Recurrent Hepatitis C After Liver Transplantation
FP-39 SA01344 16:35 - 16:45 Souheil Shabib A Twenty Year Follow-Up of 72 Children Post Liver Transplant
FP-40 SA01382 16:45 - 16:55 See Ching Chan Validating Graft and Standard Liver Size Predictions in Right Liver Living Donor Liver Transplantation
FP-41 SA01488 16:55 - 17:05 Taehoon Kim The significance of tumor biology in hepatocellular carcinoma recurrence after adult living donor liver transplantation
FP-42 SA01552 17:05 - 17:15 Shi-Chun Lu Cadaveric and Living donor Liver transplantation for acute on chronic hepatic failure patients caused by Hepatitis B: A preliminary report of 90 cases
FP-43 SA01589 17:15 - 17:25 Wei-ping Zheng Effects of tacrolimus on the expression of HBV and Cyclin A in HepG2.2.15 cell line in vitro
FP-44 SA01652 17:25 - 17:35 Nam-Joon Yi Long-term Prognosis of Intrahepatic Biliary Stricture After Non-heart-beating Donor Liver Transplantation
FP-45 SA01718 17:35 - 17:45 Zicheng Jiang A SYSTEMATIC REVIEW: COMBINATION THERAPY OF LAM AND HBIG VERSE LAM MONOTHERARY IN PROPHYLAXIS OF HEPATITIS B VIRUS RECURRENCE AFTER LIVER TRANSPLANTATION
FP-46 SA01747 17:45 - 17:55 Anthony Sebastian Experience with A2 Blood Group Donor Liver to O Blood group Recipient Liver Transplantation
FP-47 SA01754 17:55 - 18:05 W Ray Kim Accuracy of eGFRcys in Measuring Renal Function in Liver Transplant Recipients
FP-48 SA01789 18:05 - 18:15 Cong Wen-Ming The Introduction of Consensus Guidelines for the Pathological Diagnosis on Liver Transplantation Complications by Chinese Pathology Working Group on Hepatobiliary Tumors and Liver Transplantation
top
Free Paper Presentation 5: NAFLD
Date: 26 March 2010 (Friday)
Venue: Meeting Room 406
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-49 SA00226 16:15 - 16:25 Tign Wang Carnosic acid protects against obesity associated with liver steatosis in ob/ob mice
FP-50 SA00330 16:25 - 16:35 Yueyong Zhu Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits lipid accumulation in fatty liver model in vitro
FP-51 SA00676 16:35 - 16:45 Yue-min Nan Targeted genetic modulation of peroxisome proliferator-activated receptor-gamma protects against nutritional steatohepatitis and fibrosis in mice
FP-52 SA00728 16:45 - 16:55 Sher Zaman Safi Distribution of Hepatitis C Virus Genotypes, Hepatic Steatosis and their Correlation with Clinical and Virological Parameters in Pakistan
FP-53 SA00745 16:55 - 17:05 Zhao-hua Cai The protective effects of H2S on mitchondrial injury in non-alcholic steatohepatitic rats
FP-54 SA00940 17:05 - 17:15 Xiong Ma Th17 cells Integrate Hepatic Steatosis and Inflammation in Nonalcoholic Fatty Liver Disease
FP-55 SA01303 17:15 - 17:25 Shi-Ying Xuan Heritability of nonalcoholic fatty liver disease: a twin study
FP-56 SA01719 17:25 - 17:35 Abhishak C Gupta PLASMA ADIPOCYTE FATTY ACID-BINDING PROTEIN (A-FABP) LEVEL IN THE PATIENTS WITH NONALCOHOLIC STEATOHEPETITIS (NASH).
FP-57 SA00029 17:35 - 17:45 Lun-gen Lu predictors for HBeAg negative chronic hepatitis B patients with steatosis and its value in diagosis of hepatic inflammation and fibrosis
FP-58 SA00285 17:45 - 17:55 Yu-Yuan Li The incidence and associated risk factors of NAFLD in southern China: A four year follow-up population based study
FP-59 SA00308 17:55 - 18:05 Ajay Duseja Patients with nonalcoholic fatty liver disease (NAFLD) have increased atherosclerosis and cardiovascular disease risk.
FP-60 SA01439 18:05 - 18:15 Neneng Ratnasari The Risk Factors of Non-Alcoholic Fatty Liver Disease prevalence in Obesity with or without Diabetes Mellitus
top
Free Paper Presentation 6: Portal Hypertension and Biliary Tract Disease
Date: 26 March 2010 (Friday)
Venue: Meeting Room 407
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-61 SA01282 16:15 - 16:25 Ye Zhang Aberrant methylation of multiple genes in bile specimens of malignant biliary strictures
FP-62 SA01354 16:25 - 16:35 Biju Pottakkat Results of re-interventions in patients with re-stricture following high bilio-enteric anastomosis for post cholecystectomy biliary injuries
FP-63 SA00472 16:35 - 16:45 Moon Young Kim Portal hypertensive gastropathy: Correlation with portal hypertension and prognosis in liver cirrhosis
FP-64 SA00495 16:45 - 16:55 Supot Nimanong Oral L-ornithine-L-aspartate (LOLA) for patients with overt hepatic encephalopathy treated with lactulose; a randomized, double-blinded, placebo-controlled trial
FP-65 SA00518 16:55 - 17:05 Chang-Zheng Li Esophagogastric variceal bleeding was postponed by antiviral therapy in viral active hepatitis B cirrhosis
FP-66 SA00521 17:05 - 17:15 Faouzi SALIBA MARS® Albumin Dialysis as a salvage therapy in patients with end-stage liver disease and renal failure
FP-67 SA01248 17:15 - 17:25 Praveen Sharma Predictors of non response to lactulose in patients with cirrhosis and hepatic encephalopathy
FP-68 SA01338 17:25 - 17:35 Seng Gee Lim Risk factors for mortality in cirrhotic patients with sepsis
FP-69 SA01514 17:35 - 17:45 Nikhil Patel ETIOLOGICAL SPECTRUM OF CIRRHOSIS IN WESTERN INDIA
FP-70 SA01648 17:45 - 17:55 P. Patrick Basu Transdermal Rivastigmine for Treatment of Encephalopathy in Liver Cirrhosis. A Randomized Placebo Controlled Trial (T R E C – trial)
FP-71 SA01736 17:55 - 18:05 Gi-Young Ko Treatment of Postoperative Portal Vein Thrombosis: Efficacy of Balloon Angioplasty and Stent Placement
FP-72 SA00777 18:05 - 18:15 Wei Zhang Effect of intestinal flora on bacterial translocation and immune function in rats with experimental cirrhosis
top
Free Paper Presentation 7: Hepatitis B (III)
Date: 27 March 2010 (Saturday)
Venue: Meeting Room 401
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-73 SA00844 16:15 - 16:25 Jin Lin Hou FibroScan® Detecting Severity of Liver Disease Accurately in Chinese Patients with Chronic Hepatitis B
FP-74 SA00182 16:25 - 16:35 Vincent Wong A Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
FP-75 SA00375 16:35 - 16:45 Dongping Xu HBV subgenotype distribution in Chinese patients with chronic HBV infection-- a hospital-based analysis of 4,118 cases
FP-76 SA00569 16:45 - 16:55 Lin Wang The expression of miRNA in the peripheral blood mononuclear cells (PBMC) of the hepatitis B patients during virus clearance
FP-77 SA00582 16:55 - 17:05 Yu Zheng Analysis of Dimensionless Virus Infection Model with Immune and Prediction for Long-Term Therapy Effect
FP-78 SA00588 17:05 - 17:15 Xiao Chen Modeling Dynamics of Acutely Infected Chimpanzees
FP-79 SA00734 17:15 - 17:25 Yasir Waheed Prevalence and Risk factors associated with HBV transmission in Pakistani Population
FP-80 SA01616 17:25 - 17:35 Sang Hoon Ahn Prospective Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with Suboptimal Virologic Response to Lamivudine: Interim Analysis at 48 Weeks
FP-81 SA01661 17:35 - 17:45 James RG Butler The epidemiological and economic impact of chronic hepatitis B in Australia to 2017 and the cost-effectiveness of enhanced treatment
FP-82 SA01429 17:45 - 17:55 Stephan Kaiser Effectiveness of Telbivudine as Add-on Therapy in a Population of Chronic Hepatitis Patients With Suboptimal Response to Tenofovir
FP-83 SA01261 17:55 - 18:05 James Fung Profiles of HBV DNA in a large population of Chinese chronic hepatitis B patients: implications for antiviral therapy
FP-84 SA01735 18:05 - 18:15 Roberto J. Carvalho-Filho COMPARISON OF ALT AND HBV DNA LEVELS WITH HISTOLOGICAL LESIONS IN CHRONIC HEPATITIS B: IMPLICATIONS FOR TREATMENT DECISION
top
Free Paper Presentation 8: Hepatitis B (IV)
Date: 27 March 2010 (Saturday)
Venue: Meeting Room 402
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-85 SA00165 16:15 - 16:25 Xiaoguang Dou A Multicenter Cohort Study of Telbivudine in HBeAg-positive Patients With Chronic Hepatitis B (an Interim Analysis)
FP-86 SA00215 16:25 - 16:35 Hsien-Chung Yu Early vs Salvage Add-on Adefovir Therapy in Telbivudine-treated Patients Who Do Not Achieve Undetectable HBV DNA Levels at 6 Months
FP-87 SA00243 16:35 - 16:45 Guan-Huei Lee Lamivudine-Resistant Hepatitis B Patients may be Selected for Entecavir Monotherapy based on their Pre-Treatment Resistance Substitutions – A Four-Year Cohort Study.
FP-88 SA00420 16:45 - 16:55 Young-Suk Lim Lamivudine plus Adefovir or Entecavir for Patients with Chronic Hepatitis B Resistant to Lamivudine and Adefovir
FP-89 SA00480 16:55 - 17:05 Masao Omata Entecavir Five-year Resistance Data in Nucleoside-Naïve 66 fixed Japanese Patients
FP-90 SA00797 17:05 - 17:15 Ji-Dong Jia Prolonged Efficacy and Safety of 4 Years Continuous Telbivudine Treatment in Chronic Hepatitis B (CHB) Patients from GLOBE and 015 studies
FP-91 SA00928 17:15 - 17:25 Xinyue Chen Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B Infection With Peginterferon Alfa-2a [40KD] (PEGASYS) Plus Lamivudine or Adefovir for 96 Weeks Results in High Rates of HBsAg Clearance/Seroconversion
FP-92 SA00955 17:25 - 17:35 Huang Zhanlian A Pilot Study of Interferon Alpha/Peginterferon Alfa-2a Combined With Response-Guided Short-Term Nucleoside Analog Therapy in HBeAg-Positive Hepatitis B Patients
FP-93 SA00974 17:35 - 17:45 T Piratvisuth Identification of a Baseline Algorithm That Predicts Maximal Likelihood of HBeAg Seroconversion 6 months Post-Treatment With Peginterferon Alfa-2a (40KD)(PEGASYS)
FP-94 SA01092 17:45 - 17:55 Guo-rong Han A Study of the Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection
FP-95 SA01183 17:55 - 18:05 Wai Kay Seto A three-year study on viral suppression and resistance profile for treatment-naive CHB patients receiving continuous entecavir treatment
FP-96 SA01492 18:05 - 18:15 Bei Xu Ten year outcomes of lamivudine treatment in Chronic Hepatitis B (CHB) Patients with advanced liver disease
top
Free Paper Presentation 9: Hepatitis C (I)
Date: 27 March 2010 (Saturday)
Venue: Meeting Room 403
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-97 SA00112 16:15 - 16:25 Ryota Masuzaki Liver Stiffness and Duration of Infection in Patients with Transfusion-Transmitted Chronic Hepatitis C
FP-98 SA00736 16:25 - 16:35 Limin Chen Predicting treatment response in hepatitis C virus infected patients: from gene to protein expression
FP-99 SA01335 16:35 - 16:45 Liang Chen Serum ALT levels and HCV viraemia effect the complications in neonates born from HCV infected mothers
FP-100 SA00432 16:45 - 16:55 THU THUY PHAM AN OPTIMAL DURATION OF TREATMENT FOR CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS
FP-101 SA00447 16:55 - 17:05 Michael P Manns Efficacy and Safety of Telaprevir-based Regimen and 1-Year Durability of SVR in PROVE3 Study of Hepatitis C Genotype 1-Infected Patients Who Have not Responded to Prior Peginterferon-Alfa-2a/b and Ribavirin Therapy
FP-102 SA00501 17:05 - 17:15 Maribel Rodriguez-Torres Selecting patients for abbreviated treatment (16 weeks) with peginterferon alfa-2a (40KD) plus ribavirin for patients infected with HCV genotype 2/3
FP-103 SA00530 17:15 - 17:25 Piero Colombatto Simulating the decline of HCV infected hepatocytes by mathematical modelling allows for individual tailoring of Peg-IFN+RBV therapy with significant savings
FP-104 SA00545 17:25 - 17:35 Eugen Georgescu NEGATIVE PREDICTORS AFFECTING EARLY (EVR) AND SUSTAINED (SVR) VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON PLUS RIBAVIRIN
FP-105 SA00749 17:35 - 17:45 Patrick Marcellin Telaprevir q8h or q12h combined with either peginterferon (PEG-IFN, P) alfa-2a or alfa-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C patients: Final results of the randomized, open-label, multicenter Phase 2 study C208
FP-106 SA01188 17:45 - 17:55 K Patel Prospective Comparison of FibroTest and FibroScan to Predict Moderate–Severe-Stage Fibrosis in Asian Patients With Chronic Hepatitis C
FP-107 SA01190 17:55 - 18:05 A Thompson Insulin Resistance Was Independently Associated With Significant Hepatic Fibrosis in Asian Patients With Chronic Hepatitis C: Analysis of the ACHIEVE 2/3 Cohort
FP-108 SA01628 18:05 - 18:15 Naoya Sakamoto IL-28B SNPs and HCV genetic profiles, NS5A-ISDR and Core mutations are significant predictors of PEG-interferon plus ribavirin treatment outcomes
top
Free Paper Presentation 10: Hepatocellular Carcinoma (I)
Date: 27 March 2010 (Saturday)
Venue: Meeting Room 405
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-109 SA00524 16:15 - 16:25 Soo Young Park Giant symptomatic hepatic cavernous Hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation
FP-110 SA00114 16:25 - 16:35 Dengfu Yao Expression and Clinical Values of IGFII-mRNA in Patients with Hepatocellular Carcinoma
FP-111 SA00121 16:35 - 16:45 Zhendong Chen Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC): Subgroup Analyses of the Asia-Pacific (AP) Trial by Baseline Transaminase (ALT/AST)/ Alpha-Fetoprotein (AFP) and Bilirubin Levels
FP-112 SA00229 16:45 - 16:55 Dean Tian Implication of Serum Nerve Growth Factor in Patient with Hepatocellular Carcinoma
FP-113 SA00269 16:55 - 17:05 Jie Liu Cloning and functional study of novel genes and their predicting value for HCC
FP-114 SA00408 17:05 - 17:15 Jeong-Hoon Lee The BCLC System Provides the Best Discrimination Ability for Overall Survival of Untreated Hepatocellular Carcinoma Patients
FP-115 SA00863 17:15 - 17:25 Jin-Yan Zhao Prevalence of metabolic abnormalities and its association with HCC in patients with HBV infection
FP-116 SA01057 17:25 - 17:35 Long Jiang Glutamine synthetase: a novel serum marker for early hepatocellular carcinoma — proteomic analysis of small hepatocellular carcinoma
FP-117 SA01406 17:35 - 17:45 Zhenggang Ren Prognosis Difference for Hepatocellular Carcinoma with Negative or Elevated Serum AFP Treated with Transcatheter Arterial Chemoembolizaion
FP-118 SA01637 17:45 - 17:55 Myoung Ha Lee Clinical characteristics and prognosis of hepatocellular carcinoma with lower serum values of both AFP and PIVKA-II
FP-119 SA01420 17:55 - 18:05 Gul Javid Magnetic Resonace Cholangiography is Superior to Endoscopic Retrograde Cholangiography for Accurate Diagnosis of Oriental Cholangio-Hepatitis
FP-120 SA01435 18:05 - 18:15 Shinpei Sato Improving detection of liver metastases compared with enhanced CT or SPIO-MRI: Contrast-enhanced urtrasonography using Sonazoid.
top
Free Paper Presentation 11: Liver Fibrosis (II)
Date: 27 March 2010 (Saturday)
Venue: Meeting Room 406
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-121 SA00089 16:15 - 16:25 Olav A Gressner Transdifferentiation dependent inhibition of TGF-beta / Smad2/3 signaling in rat hepatic stellate cells by 1,7-dimethylxanthine
FP-122 SA00171 16:25 - 16:35 Lieming Xu Study of Contractile Mechanism of Rat Hepatic Stellate Cells Induced by Endothelin-1
FP-123 SA00212 16:35 - 16:45 Canjie Guo microRNA-16 in proliferation, activation, and apoptosis in rat hepatic stellate cells
FP-124 SA00602 16:45 - 16:55 Hui Wang NIM811 attenuates CCl4 induced liver fibrosis in rats
FP-125 SA00623 16:55 - 17:05 Fanli Meng Interleukin-17 Involved in Liver Fibrosis Induced by Carbon Tetrachloride Injection and Bile Duct Ligation
FP-126 SA00639 17:05 - 17:15 Yingdi Liu Kupffer cells and sinusoidal endothelial cells mediate the anti-fibrogenic effects of adiponectin on hepatic stellate cells
FP-127 SA00795 17:15 - 17:25 Yu-Ping Wang Effect of blueberry on hepatic and immunological functions in mice
FP-128 SA01231 17:25 - 17:35 Xin-yan Zhao A novel pirfenidone analogue F351 inhibits experimental liver fibrosis in rodents by downregulating transforming growth factor β1 (TGF-β1) and collagen I mRNA expression
FP-129 SA01368 17:35 - 17:45 Joy X. Jiang Galectin-3 Mediates Liver Fibrogenesis by Inducing Hepatic Stellate Cell Phagocytosis in vivo
FP-130 SA01369 17:45 - 17:55 Nicholas Shackel The Role of the Hepatocyte and CD147 in Chronic Liver Injury
FP-131 SA01579 17:55 - 18:05 Martin Ruehl (+)-Episesamin from Lindera obtusiloba counteracts liver fibrosis by abrogating TGF-β induced gene expression in hepatic stellate cells
FP-132 SA01723 18:05 - 18:15 Monika Kwiecinski miR29 targets the potent angiogenic and mitogenic growth factors IGF-I as well as two members of the VEGF/PDGF family
top
Free Paper Presentation 12: Acute Liver Failure
Date: 28 March 2010 (Sunday)
Venue: Meeting Room 401
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-133 SA00358 14:00 - 14:10 Vincenzo Morabito Predictive criteria for the outcome of patients with Fulminant Hepatitis after Molecular Adsorbent Recirculating System treatment.
FP-134 SA00448 14:10 - 14:20 HITENDRA GARG The APASL criteria for ACLF may overdiagnose ACLF: The role of trans-jugular liver biopsy (TJLB) and hepatic venous pressure gradient (HVPG) as gold standard
FP-135 SA00466 14:20 - 14:30 Jinhua Hu Survival analysis of the patients with HBV-related ACLF after nucleoside analogues antivirus treatment--long term follow-up after a prospective, randomized and controlled clinical study
FP-136 SA00467 14:30 - 14:40 AI Shamsul Hepatitis B Reactivation in Chronic Hepatitis B ( CHB ) Patients Receiving Chemotherapy or Immunosuppressive Therapy : Hospital Selayang Experience .
FP-137 SA00547 14:40 - 14:50 Faouzi SALIBA Albumin dialysis with MARS® as a potential indication in patients with fulminant and subfulminant hepatic failure : results from a randomized controlled multicenter trial.
FP-138 SA00575 14:50 - 15:00 Liu Fei Fluidized-bed bioartificial liver assist devices (BLaDs) based on Microencapsulated primary porcine hepatocytes have risk of PERVs transmission
FP-139 SA00620 15:00 - 15:10 Xiaoping Pan Establishment and characterization of immortalization human hepatocyte lines by transfection with simian virus 40 large T antigen
FP-140 SA01312 15:10 - 15:20 Fang Lin Balance between immunosuppression and inflammatory responses mediated by CD4+CD25+FOXP3+ regulatory T cells and Th17 cells determines the outcome of acute HBV hepatitis and acute-on-chronic liver failure
FP-141 SA01329 15:20 - 15:30 Rongrong Zhou Release and Translocation of HMGB1 in hepatocytes and its potential significance in acute on chronic liver failure
FP-142 SA01531 15:30 - 15:40 Kazuaki Inoue New treatment strategy for fulminant hepatitis in Japan
FP-143 SA01691 15:40 - 15:50 Vishal Garg GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) THERAPY COULD IMPROVE SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) - A RANDOMIZED PLACEBO CONTROLLED TRIAL
FP-144 SA01710 15:50 - 16:00 Nirupma TrehanPati Cellular immune profiling in peripheral blood, hepatic vein blood and in the liver in patients with acute on chronic liver failure (ACLF)
top
Free Paper Presentation 13: Hepatitis C (II)
Date: 28 March 2010 (Sunday)
Venue: Meeting Room 402
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-145 SA00535 14:00 - 14:10 Muhammad Umar Prevalence of Hepatitis - C in Pakistan
FP-146 SA00900 14:10 - 14:20 Banishree Saha Effector memory T cells and PD-1 expression in HCV/HIV coinfection results in reduced immune response.
FP-147 SA01713 14:20 - 14:30 Manish Chandra Choudhary Overexpression of PD-1 during chronic HCV (CHC) infection impairs the antiviral function of CD8+ T lymphocytes.
FP-148 SA00174 14:30 - 14:40 Run-Xuan Shao Nucleosome Assembly Protein 1 (Nap 1) Binding to Hepatitis C Virus NS5A and Increased HCV Replication
FP-149 SA00339 14:40 - 14:50 Ronglin Zheng mRNA levels of FBP,TBC1D20 were found to be up-regulated in the peripheral blood mononuclear cells of untreated chronic HCV-infected patients
FP-150 SA00494 14:50 - 15:00 Zhongjie Hu Quantitative Analysis of Hepatitis C Virus Genotype 1b Core Codon 70 Wild Type and Mutant and the Response to PEG-IFN/RBV Treatment
FP-151 SA00497 15:00 - 15:10 Ryo Tamura HEPATITIS C VIRUS NONSTRUCTURAL PROTEIN 5A DOWNREGULATES TOLL-LIKE RECEPTOR-4 SIGNALING AND BLOCKS LPS-INDUCED APOPTOSIS IN HEPATOMA CELL LINES
FP-152 SA01056 15:10 - 15:20 Xiaoyu Li Inhibitory effects of IRF3 on hepatitis C viral replication
FP-153 SA01156 15:20 - 15:30 Juandy Jo Central role of CD8+ T-cell-mediated non-cytolytic effector functions for inhibition of hepatitis C virus replication
FP-154 SA01364 15:30 - 15:40 Jun-qi Niu Th1/Th2 immune responses in Chinese chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil
FP-155 SA01578 15:40 - 15:50 Shinya Maekawa HCV Genetic Elements Determining the Response to Peginterferon + Ribavirin Therapy
FP-156 SA01667 15:50 - 16:00 Rongjuan Pei Amphiregulin expression in hepatitis C virus infection
top
Free Paper Presentation 14: Hepatocellular Carcinoma (II)
Date: 28 March 2010 (Sunday)
Venue: Meeting Room 403
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-157 SA00180 14:00 - 14:10 Hui Yang Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells
FP-158 SA01331 14:10 - 14:20 Xue-Gong Fan The potential significance of high mobility group box 1 in hepatocellular carcinoma development
FP-159 SA01379 14:20 - 14:30 Liang Liu Activation of β-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis
FP-160 SA01396 14:30 - 14:40 Seng Gee Lim Polo-Like Kinase 1, A New Therapeutic Target In Hepatocellular Carcinoma
FP-161 SA01538 14:40 - 14:50 Osamu Kimura EpCAM as a useful marker for defining tumor initiating cells in hepatocellular carcinoma
FP-162 SA01564 14:50 - 15:00 Adam Gehring Engineering Virus-specific T cell immunity to Target Chronic Hepatitis B Virus Infection and HBV-related Hepatocellular Carcinoma.
FP-163 SA01727 15:00 - 15:10 Natalia Elfimova Influence of microRNA-125b repression in the pathogenesis of hepatocellular carcinoma
FP-164 SA01770 15:10 - 15:20 Francesca Guerrieri HBx transcriptome in HCC cells replicating HBV: a chromatin-immunoprecipitation (ChIP and ChIP-Seq) study
FP-165 SA01339 15:20 - 15:30 Cosmas Rinaldi A Lesmana Clinical Aspects of Hepatocellular Carcinoma in A Single Hospital in Jakarta
FP-166 SA00608 15:30 - 15:40 Minshan Chen HCC BRIDGE Study: Expanding Knowledge of Hepatocellular Carcinoma Treatment and Outcomes in China
FP-167 SA01669 15:40 - 15:50 Kyu Sik Jung Risk assessment for the development of hepatitis B virus-related hepatocellular carcinoma by transient elastography
FP-168 SA01752 15:50 - 16:00 Lu Xin-Yuan Hepatocellular carcinoma expressing dual phenotypes is a nique subtype
top
Free Paper Presentation 15: Miscellaneous
Date: 28 March 2010 (Sunday)
Venue: Meeting Room 405
Presentation No. Submission No. Presentation Time Presenting Author Presentation Title
FP-169 SA01187 14:00 - 14:10 Michel Beaugrand Controlled Attenuation Parameter for the Detection and Quantification of Steatosis - Preliminary Study in an Alcoholic and Non-Alcoholic Steato-Hepatitis Cohort -
FP-170 SA01310 14:10 - 14:20 Angela Dolganiuc Alcohol inhibits Bcl-2/beclin-1 branch of LPS-induced autophagy in the liver.
FP-171 SA01686 14:20 - 14:30 Wei Zhong Impact of zinc on histone deacetylase and NF-kappa B in alcohol-induced IL-8 production and hepatitis
FP-172 SA00334 14:30 - 14:40 Atsushi Tanaka The functional polymorphism in the promoter region of Fc receptor-like 3 (FCRL3) is strongly associated with susceptibility of primary biliary cirrhosis
FP-173 SA01311 14:40 - 14:50 Enrico Roda 13 Years Follow-up in Primary Biliary Cirrhosis Patients (I-II stage): evaluation of Standard vs High UDCA dose, a randomized open controlled trial
FP-174 SA01496 14:50 - 15:00 Zhe-Xiong Lian The mechanism of CD4+ and CD8+ T cell subset in autoimmune liver disease
FP-175 SA00450 15:00 - 15:10 Dominik Huster Copper toxicity results in cardiolipin fragmentation, structural damage and malfunction of mitochonria in Atp7b-/-mice an animal model of Wilson disease
FP-176 SA01775 15:10 - 15:20 Barbara Testoni IFN-α/β target genes modulated by exogenous type I IFN and by the endogenous HBV-induced IFN-response in liver cells
FP-177 SA00247 15:20 - 15:30 Lei Li Establishment of Immunocompetent Hepatitis B Virus Chronically Infected Mouse Model of Genotype B
FP-178 SA01051 15:30 - 15:40 Qiuwei Pan Innate transmission of small RNA between human cells extends the therapeutic reach of RNAi for hepatitis C
FP-179 SA01431 15:40 - 15:50 Yock Young Dan Liver Stem Cell Niche
FP-180 SA01731 15:50 - 16:00 Beatriz Calle Serrano Hepatitis Delta clinical Outcome: a 15 year European experience
top

Poster Presentations

Poster Presentations: Hepatitis B
Presentation No. Submission No. Presenting Author Title
PP-001 SA00326 Liu Ying JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection but not with α interferon therapy response in Han Chinese population
PP-002 SA00383 Su Jong Yu Putative Association of DNA Methyltransferase 1 (DNMT1) Polymorphism with Risk of Human Hepatocellular Carcinoma among Chronic HBV Patients
PP-003 SA00452 Xiaomei Xu The Relationship Between HBeAg And HBV Persistent Infection
PP-004 SA00600 Hasmik Ghazinyan The Prevalence of Hepatitis B and C Virus Infection in Oncological Patients
PP-005 SA00969 HOU Zhouhua Retrospective analysis of 79 chronic severe hepatitis patients with invasive fungal infection
PP-006 SA00988 Eun Young Cho Epidermiological Study of Prognostic Factor in Occult Hepatitis B Virus Infection
PP-007 SA01461 Kui-xia Sun The Distribution of Hepatitis B Virus Genotypes and Sub-genotypes in China
PP-008 SA00063 Ching-Sheng Hsu Patients with Chronic Hepatitis B have Favorable Metabolic Profiles: A Case-Control Study
PP-009 SA00085 Zhonghua Lu Five years follow-up study of 220 chronic HBV carriers
PP-010 SA00110 Karen Batoctoy HBV/A and HBV/C Genotype Predominance among Patients with Hepatitis B virus Infection in Cebu City, Philippines
PP-011 SA00126 Shahinul Alam Lifetime Exposure Rate Of Hepatitis B Virus In A Rural Area Of Bangladesh And Possible Route Of Transmission
PP-012 SA00205 Fariborz Mansour- Ghanaei Prevalence of Hepatitis B and C in Hemodialysis Patients in Guilan, North Province of Iran
PP-013 SA00443 Chien-Hsieh Chiang Metabolic Factors and HBV DNA Levels
PP-014 SA00461 Heon Ju Lee Risk assessment for hepatocellular carcinoma development according to on-treatment virological responses during long-term lamivudine therapy in hepatitis B virus-related liver diseases
PP-015 SA00622 Burcak Evren Tasdogan THE FREQUENCY OF HEPATİTİS B INFECTION IN PATIENTS WİTH ULCERATIVE COLITIS, DO THEY HAVE AN INCREASED RISK FOR VIRAL HEPATITIS?
PP-016 SA00641 Makoto Arai Analysis of Long-term Follow-up in Patients with Hepatitis B e Antigen Negative Chronic Hepatitis B
PP-017 SA00668 Jing-jing NIE D1: Major Subgenotype of Hepatitis B Virus among Uigur Patients in Xinjiang Uygur Autonomous Region of China
PP-018 SA00698 Junying Qi Outcomes in 161 Patients with Decompensated Hepatitis B: A Single Center Study
PP-019 SA00717 Zhan Yang The relationship between disease progression in patients with chronic hepatitis B and gene copy number variation of PD-1
PP-020 SA00748 Yagaanbuyant Dahgwahdorj Epidemiological changing of HBV infection in Mongolia
PP-021 SA00835 Wei Zhang A Cross-Sectional Study of Hepatitis B Vaccination Rate in High Risk Adult Population in Beijing
PP-022 SA00918 Jian Gong Impact of HBsAg carriage of mothers on effectiveness and persistence of Hepatitis B vaccine immunization
PP-023 SA01042 Tao Han To investigate the cause and clinical outcome of 289 HBV infection patients with acute-on-chronic liver failure (ACLF)
PP-024 SA01117 IOANNIS ELEFSINIOTIS Vaccination-induced protection rates against hepatitis B among pregnant women in Greece: far away from the ideal target.
PP-025 SA01195 Xiang-sheng Xu Exhaustion of HBsAg-Specific B-cell Response Correlates with Liver Pathogenesis during Chronic Hepatitis B Virus Infection in Humans
PP-026 SA01196 Zheng Zhang Cytokine-dependent up-regulation of natural killer cell cytotoxicity associate with liver damage and fibrosis in patients with chronic hepatitis B
PP-027 SA01237 Benjamin Cowie Outcomes of a complex dynamic mathematical model of hepatitis B virus in Australia
PP-028 SA01238 Benjamin Cowie Developing a mathematical model of hepatitis B in Australia – a new way of engaging an ancient, emergent pathogen
PP-029 SA01265 Moon Seok Choi A Multi-center, Nation-wide, Cross-sectional, Epidemiologic Study to Investigate Clinical and Laboratory Characteristics of HBeAg Positive and Negative Chronic Hepatitis B Patients in Korea
PP-030 SA01309 Chao shuang Lin Status of HBV infection and vaccination among health care workers in a public teaching hospital
PP-031 SA01313 Jun Wu Enhanced Surveillance of Acute Hepatitis B in Canada, 1998 to 2008
PP-032 SA01327 Li Wanyu Association of IFN-λ gene in the Chinese han population with hepatitis B virus infection
PP-033 SA01401 Hong-Ying Chen The variation of serum level of interleukin-15 and it’s significances in patients with chronic hepatitis B virus infection
PP-034 SA01412 Xie Tiansheng Development and Validation of HBQOL-cn
PP-035 SA01454 Hairong Wei Inhibitory receptor NKG2A tempers NK cells against hepatitis B virus in active chronic hepatitis B
PP-036 SA01505 Hsiu-Lien Hung Incidence and Determinants for Hepatitis B e Antigen Seroclearance
PP-037 SA01526 Chuen-Fei Chen Long-term repeated measurements of hepatitis B viral load and the risk of HCC
PP-038 SA01527 Wei-Ju Su Reduction of the Incidence of Acute Hepatitis B after Universal Hepatitis B Immunization Program in Taiwan
PP-039 SA01560 Seong Woo Lim Virological and Clinical Features in Patients with HBsAg Seroclearance after Antiviral Treatment
PP-040 SA01572 Manash Sarma Hepatitis B Seroprevelance in Liver Disease Patients from India: Correlation between HBeAg Status, HBV Viral Load and Genotypes
PP-041 SA01581 Jing Liu The Epidemiological Features of Spontaneous Decrease of HBV DNA Level in CHB/LC Patients in South China
PP-042 SA01720 Hasan Ozkan Loss of HBsAg antigen in 894 HBsAg+ Patients During Long Term Follow Up
PP-043 SA01771 Anca Trifan Usefullness of transient elastography and Fibrotest to differentiate inactive hepatitis B carriers from HBe Ag-negative chronic hepatitis B
PP-044 SA00145 Xing Tongjing Effect of different markers on the study of T regulatory cells in patients with chronic hepatitis B infection
PP-045 SA01256 Ying-Tang Gao Measurement of Covalently Closed Circular DNA of Hepatitis B Virus by Real-time PCR and Its Preliminary Application
PP-046 SA01291 Ichiro Kumagai Differences among genotype, subgenotype, and mutation of precore and corepromoter regions of hepatitis B virus in patients with self-limiting acute hepatitis both in Japan and China
PP-047 SA01678 Lubiao Chen Relationship between SNP rs2660 on OAS-1 Gene and Spontaneous HBeAg Seroconversion in Chronic HBV Infection
PP-048 SA00083 HU Ai-rong Comparison of quantitative fluorescent polymerase chain reaction（QF-PCR） with the COBAS TaqMan test for hepatitis B virus(HBV) DNA in serum samples and clinical analysis of HBV-DNA in different clinical features
PP-049 SA00117 Shuhei Hige Hepatitis B core-related antigen in association with hepatocellular carcinoma.
PP-050 SA00198 Fariborz Mansour-Ghanaei Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province,Iran
PP-051 SA00203 Farahnaz Jokar Occult Hepatitis B virus infection in hemodialysis patients of Rasht
PP-052 SA00223 Weiliang Tang Risk Factors of Prognosis for Patients with Severe Hepatitis B
PP-053 SA00228 Amarsanaa Jazag Current status and paradox in HBV diagnosis and management in Mongolia
PP-054 SA00350 Yongnian HAN Scoring systems based on laboratory tests for identifying acute hepatitis B among patients firstly presenting hepatitis B virus-related acute hepatitis
PP-055 SA00427 Ioannis Elefsiniotis Spontaneous preterm birth in women with HBeAg-negative chronic hepatitis B virus (HBV) infection. The value of maternal and cord blood data.
PP-056 SA00428 Ioannis Elefsiniotis Spontaneous preterm birth is associated with HBsAg-positive status among pregnant women in Greece.
PP-057 SA00539 Yeon Seok Seo A simple and accurate algorithm for avoiding unnecessary liver biopsy in patients with chronic hepatitis B
PP-058 SA00624 Maurizia R. Brunetto HBsAg serum levels help to identify inactive, genotype D, HBV carriers
PP-059 SA00839 Jun LI Dynamic Change of Specific CTLs in Patients with Acute Hepatitis B
PP-060 SA00914 Yuexin Zhang Carboxyhemoglobin levels and its clinical significance in patients with viral hepatitis
PP-061 SA00946 Rui Zhang Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen mutants
PP-062 SA00984 Shao-lin Zhao Quantitative detection of hepatitis B virus in peripheral blood mononuclear cells during the course of treatment patients with chronic hepatitis B
PP-063 SA00987 Jiawu Song The Development of Biosensor-based Microarray for HBV Genotyping and Preliminary Clinical Study
PP-064 SA01012 Li-Yuan Wang Aberrant statue of oxidative stress in chronic hepatitis B patients with elevated serum total bilirubin
PP-065 SA01075 SU zhi-jun Study on peripheral blood lymphocytes subsets in patients with chronic hepatitis B infection
PP-066 SA01124 Mamun Mahtab Study of fibroscn as a non-invasive marker of liver fibrosis in patients with chronic hepatitis B
PP-067 SA01142 Jia-ji Jiang An investigation on relevant factors of hepatic steatosis in patients with chronic hepatitis B
PP-068 SA01229 Tao Han Serum Thymosin β4 Levels in Liver Failure Patients Caused by Chronic Hepatitis B Virus Infection
PP-069 SA01366 Jing You The variation of peripheral T-lymphocyte subpopulations and serum interferon-γ and interleukin-4 levels in patients with chronic hepatitis B virus infection
PP-070 SA01456 Chao Zhao Identification of Autoantibodies in Sera of Hepatitis B Virus Transgenic Mice
PP-071 SA01489 Seiko Togo Clinical Significance of Measurement of HBs antigen in Chronic Hepatitis B Virus-Infected Patients with HBe antigen
PP-072 SA01512 Hwai-I Yang Development and Validation of a Predictive Risk Score for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
PP-073 SA01530 Xieer Liang Liver Stiffness Measurement in Patients with Hepatitis B Flare Influenced Majorly by Bilirubin: Is There still a Role for Alanine Aminotransferase?
PP-074 SA01724 Xiangdong Ren Quantitative analysis of HBV mutants may help understand viral pathogenesis
PP-075 SA01746 Shuang Meng Nuclease-resistant double-stranded DNA controls or standards for hepatitis B virus nucleic acid amplification assays
PP-076 SA01765 Yuming Wang Mechanism of HBV-related Liver Failure
PP-077 SA00100 Dipendra Raj Pandeya Expression and Purification of a Functional Human HBV Polymerase
PP-078 SA00625 Chien-Hung Chen Risk Predictors of Reactivation of Hepatitis B Virus Following HBeAg Seroconversion in Chronic Hepatitis B Patients with or without Interferon-based Therapy
PP-079 SA00627 Ting-Chih Chen Evolution of HBV genomes in HBeAg-positive carriers: Comparison between genotype B versus C at different stages
PP-080 SA00773 Chang Soo Choi Associations Between the X Gene Mutations and Clinical Severity of Liver Disease in Patients With Chronic Hepatitis B Virus infection
PP-081 SA01133 Lin Yang NH2-terminal region of Hepatitis B virus X protein is required for functions of HBx :promoting growth and proliferation of hepatocellular carcinoma cell via induction of cell cycle progression
PP-082 SA01374 Seng Gee Lim Core Internal Deletions in Spontaneous, Interferon-induced or Lamivudine treated HBeAg Seroconverter patients
PP-083 SA01509 Antonio Bertoletti T cell receptor-like antibodies targeting HBV infected hepatocytes: a new tool for drug delivery and pathogenic studies.
PP-084 SA00040 Jie Li STAT1 demethylation is involved in the resistance of Hepatitis B Virus to Interferon alpha
PP-085 SA00061 Ye Zhang Overexpression of Toll-like receptor 2/4 modulates the activities of CD4+CD25+ regulatory T cells in chronic hepatitis B virus infection
PP-086 SA00067 Mamun Mahtab PROFILE OF HBeAg -VE CHRONIC HBV INFECTION IN BANGLADESH
PP-087 SA00127 Yasuteru Kondo Heat shock proteins derived from HBV-infected-hepatocyte enhance the function of regulatory T cells by TLR2 signaling
PP-088 SA00158 Wen-Chun Liu Correlation between mutation and methylation of CpG islands of hepatitis B virus and viral kinetics in natural course patients
PP-089 SA00227 Jie Li HBcAg induces Interleukin 10 inhibits HBcAg-specific Th17 responses in Chinese chronic hepatitis B patients
PP-090 SA00264 Hui Chen Expression and localization of APOBEC3G in PBMC and liver tissue in different chronic HBV infected patients
PP-091 SA00294 Zhang Zhenhua Establishment and mutation analysis of the reference sequences for HBV genotypes B and C that are prevalent in China
PP-092 SA00313 Dongping Xu Features and clinical implications of HBV genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B
PP-093 SA00318 Dongping Xu Association of HBV mutations in basal core promoter and precore regions with severity of liver disease--an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure
PP-094 SA00335 Yue-Yong Zhu siRNA alters the proliferation of hepatocellular carcinoma cell line HepG2 via reducing the expression of COX-2 gene
PP-095 SA00337 Jia-ji Jiang Clinical significance of hepatocyte expression of HBV surface antigen
PP-096 SA00346 Ye Zhang Th17 cells correlate with acute but not chronic hepatitis B virus infection
PP-097 SA00406 Zhao Yongxiao Relationship between local cellular immune in liver and viral replication in different phases of chronic HBV infection
PP-098 SA00416 Xiao Gang Huang Vα24 NK T cells in peripheral blood and their correlations with the severity of hepatic injury in patient with chronic hepatitis B virus infection
PP-099 SA00434 Shuang Wu Hepatitis B e antigen suppresses innate immune response
PP-100 SA00464 Du Juan Evaluation of two HBV Promoters for Sustained Transgene Expression in Mouse Liver
PP-101 SA00471 ROLI SAXENA Association of IL-12 and Interferon - gamma genotypes in the progression and development of HBV-related hepatocellularcarcinoma in India
PP-102 SA00491 Jialun Yu The primary study on the relationship between the characteristic of the hepatitis B virus S gene quasispecies and the clinical outcomes of HBV infection
PP-103 SA00513 Naichaya Chamroonkul Utility of INNO-LiPA HBV DR v2 Testing in Chronic Hepatitis B Patients who Developed Viral Breakthrough During Oral Nucleos(t)ide Analogues Treatment
PP-104 SA00567 Shao Qiang Wu Comparative analysis of the TCR beta chain CDR3 spectratyping of infiltrating T lymphocytes in the liver and in peripheral blood in patients with chronic hepatitis B
PP-105 SA00573 Jingxian Yang Detection of antiviral resistance mutations in HBV C-genotype chronically infected Chinese patients with or without antiviral treatment
PP-106 SA00596 Lingli Yang Serum HBV RNA in patients with chronic hepatitis B virus infection
PP-107 SA00702 Sayabold Batmunkh Current distribution of HBV serological markers in chronic HBV patients and its significance in Mongolia
PP-108 SA00755 Xin Zhang Mutation in BCP and precore region of HBV genome was in connection with the progression of the chronic hepatitis B
PP-109 SA00759 Hong Tang Application of the HBV replication mouse model in the biological study of HBV
PP-110 SA00760 Hong Tang Hepatitis B virus X protein augments HBV transcription and replication in vivo
PP-111 SA00771 Cai QingXian Expression of Suppressor of Cytokine Signaling-1 Gene in PBMC of Hepatitis B Virus-related Liver Diseases and Its Clinical Significance
PP-112 SA00786 Mindie H. Nguyen Hepatitis B virus reverse transcriptase mutations (rt) were not detected in treatment-naïve patients with chronic hepatitis B (CHB) patients using sensitive INNO LiPA HBV DR3 in a prospective community-based study
PP-113 SA00818 Xue-ping Nan Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection
PP-114 SA00903 CHENGHUI HUANG Detection of hepatitis B virus DNA in blood donors with HBsAg negative but anti-HBc positive and analysis of S gene variation
PP-115 SA00907 Jian-qi Lian Th17 cells correlate with acute but not chronic hepatitis B virus infection
PP-116 SA00957 Wu Jing Characteristics and clinical significance of peripheral blood NK cells subsets in patients with chronic hepatitis B virus infection
PP-117 SA01050 Zhen-Ping Wu The resistance mutation pattern of hepatitis B virus during adefovir dipivoxil sequential therapy after lamivudine resistance
PP-118 SA01096 Pattaratida Sa-nguanmoo Virological factors of hepatitis B virus associated with vaccine failure in Thailand
PP-119 SA01113 Nauman Arif Jadoon Hepatitis B Vaccination Status of Health Care Workers at a Tertiary Care Hospital In Multan
PP-120 SA01122 Lei Lu Early Viral Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B Patients Treated with Lamivudine or Clevudine Therapy
PP-121 SA01127 Mamun Mahtab Profile of HBeAg -ve Chronic HBV Infection in Bangladesh
PP-122 SA01260 Zhen-Ping Wu The evolution of hepatitis B virus quasispecies during sequential therapy after lamivudine resistance
PP-123 SA01321 Ning Li Expression level of toll-like receptors and the prognosis of chronic severe hepatitis B
PP-124 SA01328 Li Wanyu The imbalance of B lymphocyte subsets in chronic HBV infection
PP-125 SA01362 Pu-jun Gao Beta 2-glycoprotein I binds to hepatitis B surface antigen
PP-126 SA01370 Seng Gee Lim Viral Quasispecies Evolution Pattern In Chronic Hepatitis B Patients Treated With Lamivudine
PP-127 SA01419 Zhiping Qian Expression of nuclear factor-κB and its regulated cytokines in dendritic cells in patients with chronic severe hepatitis B and its clinical significance
PP-128 SA01444 Bin Zhou A case with triplicate genotypes infection showed evidence for recombination of HBV
PP-129 SA01448 Dong Jiu Zhao Involvement of p38 signaling pathway in the process of antiviral activity of A3G toward Hepatitis B Virus
PP-130 SA01557 Vlad Ratziu Modelling the impact of treatment with entecavir on long-term mortality, morbidity and healthcare costs of chronic hepatitis B in France
PP-131 SA01608 Jerzy Jaroszewicz Hepatitis B Surface Antigen (HBsAg) Levels in the Natural History of Hepatitis B Virus (HBV)-Infection: A European Perspective
PP-132 SA01708 Don Ha LI Study on the Relationship Between The HBV cccDNA copies of Hepatocytes and Serum HBV DNA'HBsAg in Chronic Hepatitis B Patients
PP-133 SA01776 Laura Belloni STAT1/2 transcription factors in the control of cccDNA transcription and HBV replication
PP-134 SA00207 Yidan Qian 48 weeks observation of Telbivudine in treatment of chronic severe hepatitis B
PP-135 SA00899 Lunli Zhang The significance of ISG15/USP18 expression in predicting response to interferon therapy for chronic hepatitis B
PP-136 SA00906 Xi Zhang Patients receiving entecavir with a partial virologic response at week 48 achieved HBV DNA undetectable at year 2 with no change of therapy
PP-137 SA00915 Myoung Hee Lee Efficacy of Entecavir in Patients with Hepatitis B Virus-related Decompensated Liver Cirrhosis
PP-138 SA00921 Şükran Köse Results of Entecavir Treatment in Chronic Hepatitis B (CHB) Patients
PP-139 SA01244 Jeong Han Kim Comparision of Clevudine and Entecavir as primary treatment for Chronic Hepatitis B
PP-140 SA01388 Yi-Hsiang Huang Analysis of short-term survival of lamivudine treatment in patients with decompensated cirrhosis related to hepatitis B
PP-141 SA01390 Byung Hoon Han Long-term adefovir mono therapy in patients with lamivudine-resistant chronic hepatitis B
PP-142 SA01480 Scott Bowden Quantification of hepatitis B surface antigen: evaluation of the Roche Elecsys® prototype HBsAg quantification assay.
PP-143 SA01619 Hyun Woong Lee Entecavir Rescue Therapy versus Adefovir Combination Therapy in Lamivudine-refractory Patients with Chronic Hepatitis B
PP-144 SA00038 Hao Wang Long term efficacy of nine-year Lamivudine treatment in chinese chronic hepatitis B patients with advanced liver fibrosis.
PP-145 SA00065 Mamun Mahtab SEQUENTIAL TREATMENT OF CHILDREN WITH CHB IN IMMUNOTOLERANT PHASE WITH LAMIVUDINE AND INTERFERON
PP-146 SA00066 Mamun Mahtab ANTIVIRAL POTENTIALITY OF A COMBINATION THERAPY (ANTIVIRAL AND IMMUNE THERAPY) IN INCIDENTALLY-DETECTED CHRONIC HEPATITIS B VIRUS-INFECTED SUBJECTS (IDHAS) IN BANGLADESH
PP-147 SA00086 Yida Yang De novo lamivudine and adefovir dipivoxil combination therapy for patients with decompensated cirrhosis resulting from chronic hepatitis B.
PP-148 SA00094 Li-jie Sun Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure
PP-149 SA00120 Truong BaTrung A STUDY OF PEG-IFN ALPHA-2A (PEGASYS) TREATMENT IN HBeAg-POSITIVE CHRONIC HEPATITIS B
PP-150 SA00170 Li-Jun Mi Use of Tenofovir DF (TDF) in Chinese-American Pregnant Patients with Chronic Hepatitis B (CHB)- Case Series Report
PP-151 SA00189 Md. Golam Azam Lamivudine for chronic hepatitis B virus infection: efficacy and drug resistance during long-term treatment
PP-152 SA00193 Su Sheng Combination treatment of chronic hepatitis B using interferon alpha and anti-HBV specific active immunotherapy
PP-153 SA00201 Yong-Ning Xin The Effects Of Acidic Mucopolysaccharide From Stichopus Japomicus Selenka On HBV Transgenic Mice
PP-154 SA00235 Mamun Mahtab Initial 1 Year Experience with Telbivudine in Bangladesi CHB Patients
PP-155 SA00245 Yue-qiu Gao Effect of Bushen Recipe on immune effector molecules of T lymphocytes
PP-156 SA00258 Jian guo Yu The analyse of effectiveness and safety in Chronic hepatitis B treated by adefovir dipivoxil combined with bicyclol
PP-157 SA00259 Jian guo Yu Study of liver biopsy in chronic HBV carriers
PP-158 SA00262 Yanqing Huang Therapeutic effects of N-acetylcysteine on the patients with chronic severe hepatitis B
PP-159 SA00274 Md. Golam Azam Peginterferon alfa-2b (12 KD) in chronic hepatitis B patients in Bangladesh: A preliminary study
PP-160 SA00277 Dongying Xie Telbivudine Induces Marked Inhibition of PD-1 Expression and Enhances IFN-γ and CD8+ T-cell Production in HBeAg-positive Patients With CHB Who Achieve Early HBeAg Seroconversion
PP-161 SA00331 Sheng Su Study on immune effects of anti-HBV specific active immunotherapy(SAI) in the treatment of Chinese chronic HBV infection.
PP-162 SA00332 Jia-ji Jiang The potential of dendritic cells-derived exosomes in immunotherapy of chronic hepatitis B infection
PP-163 SA00336 Jia-ji Jiang Predictors of Adefovir dipivoxil monotherapy to HBeAg positive patients
PP-164 SA00341 Yuexin Zhang CD4+CD25+ regulatory T cells decline in patients with chronic severe hepatitis B
PP-165 SA00390 Ed Gane TENOFOVIR PROVIDES EFFECTIVE RESCUE THERAPY FOR PATIENTS FOLLOWING TREATMENT FAILURE WITH ADEFOVIR THERAPY
PP-166 SA00439 S. Nimanong Telbivudine Add-on Therapy for a Cirrhotic Patient with Chronic Hepatitis B Who Failed Sequential Treatment with Lamivudine/Adefovir: A Case Report
PP-167 SA00475 Yang-fang Jiang Enhancing anti-hepatitis B virus mediated immune response by nucleos(t)ide analogs and Thymosin-alpha1 therapy
PP-168 SA00476 HUEI-RU CHENG Outcome of chronic hepatitis B patients receiving peginterferon alfa-2a therapy in Taiwan: A Single Center Experience
PP-169 SA00490 Qing Xie Long term efficacy of entecavir therapy on viral suppression in nucleoside-naïve chronic hepatitis B Patients
PP-170 SA00515 Soo Young Park Early Development of Clevudine Resistance in Chronic Hepatitis B Patients with Prior Lamivudine Therapy
PP-171 SA00529 Sae Hwan Lee LAMIVUDINE-ADEFOVIR COMBINATION THERAPY COULD NOT SUFFICIENTLY CLEAR THE INITIAL YMDD MUTANTS IN HBEAG-POSITIVE PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B
PP-172 SA00555 June Sung Lee Initial Viral Response is the Most Important Predictor of the Emergence of Resistant Mutants after Adefovir Treatment in Lamivudine-Resistant Chronic Hepatitis B
PP-173 SA00556 Chun Kyon Lee Comparison of Entecavir and Clevudine for treatment of Chronic Hepatitis B
PP-174 SA00568 Hong You Two patterns of ALT flare to predict long-term viral response after nucleos(t)ide treatment in HBeAg-positive chronic hepatitis B patients: Virus-induced or Host-induced?
PP-175 SA00595 Golam Azam Telbivudine in chronic hepatitis B: One-year result among Bangladeshi patients
PP-176 SA00653 Jia-ji Jiang Efficacy of domestic Adefovir dipivoxil (AGD) monotherapy to chronic hepatitis B
PP-177 SA00654 YS Lee Treatment with Clevudine Results in Sustained Antiviral Response Associated with Continued HBsAg Decrease Additional 2-Year Post-Treatment in Chronic Hepatitis B Patients
PP-178 SA00655 Yimin Mao Efficacy and safety of one year therapy with adefovir dipivoxil (ADV) in a large sample of Chinese patients with chronic hepatitis B (CHB)
PP-179 SA00657 Li Jun Colligation Analysis And Evaluation On The Efficacy Of Combined Traditional Chinese Medicine And Western Medicine For Severe Hepatitis
PP-180 SA00661 Jia-ji Jiang Short-term therapy of entecavir versus laminvudine for hepatitis B virus associated acute hepatic failure
PP-181 SA00686 M C Ngu Severe Osteomalacia and Hypophosphataemic Renal Tubular Dysfunction in 2 Patients on Long Term Adefovir Dipivoxil for Chronic Hepatitis B
PP-182 SA00733 En-Qiang Chen Biochemical and virological response of adefovir dipivoxil and entercavir for the treatment of naïve chronic hepatitis B patients in China
PP-183 SA00780 Ena Lyn Ang Entecavir in Lamivudine-Refractory Chronic Hepatitis B Infection—A Meta-Analysis
PP-184 SA00787 Sang-Hoon Ahn Telbivudine combination with Adefovir vs Adefovir monotherapy in HBeAg positive Chronic Hepatitis B (CHB) patients with lamivudine resistance
PP-185 SA00799 Mindie Nguyen Complete virologic response (CVS) to entecavir (ETV) therapy in adefovir (ADV) experienced patients: A Multicenter Study.
PP-186 SA00804 Mindie H. Nguyen Long-term outcome in treatment-naïve HBeAg-negative chronic hepatitis B (CHB) patients treated with entecavir 0.5mg (ETV) or adefovir 10mg (ADV) in a real-life clinical setting
PP-187 SA00806 Karsten Wursthorn Quantitation of Serum HBeAg Levels During Prolonged Telbivudine Treatment and Correlation with Outcome
PP-188 SA00807 Karsten Wursthorn Serum HBsAg Kinetics in HBeAg-Positive (+) Patients During 3 Years Telbivudine Treatment in Chronic Hepatitis B (CHB)
PP-189 SA00810 Aldo Trylesinski Outcomes for newborns exposed to telbivudine during pregnancy. Retrospective analysis of the Novartis safety and clinical databases
PP-190 SA00814 Hong Ren Telbivudine induced HBeAg Seroconversion in Chronic Hepatitis B (CHB) patients is durable during 2 years off-treatment follow-up
PP-191 SA00817 In Hee Kim Virologic Response and Resistance of 48-Week Entecavir Therapy Versus Clevudine in Naïve Patients with Chronic Hepatitis B
PP-192 SA00826 Henry LY Chan Efficacy and safety of telbivudine vs lamivudine in the treatment of decompensated Chronic Hepatitis B (CHB) for 2 years
PP-193 SA00840 TATSUO KANDA Secondary Antiviral Treatment Failure against Hepatitis B Virus by Nucleos(t)ide Antivirals
PP-194 SA00850 Meiqin Zhu Efficacy And Safety Of Lamivudine For Preventing Mother-to-infant Transmission Of HBV-A Systematic Review.
PP-195 SA00861 Marie Ellaine Velasquez Lamivudine in Hepatitis B Reactivation in Patients with Rheumatologic Diseases on Chronic Immunosuppression
PP-196 SA00869 Il Han Song Clinical Efficacy of Adefovir Mono-switch versus Adefovir Add-on Therapy in Patients with Lamivudine-resistant Chronic Hepatitis B
PP-197 SA00887 Jeong Han Kim Comparision of Clevudine and Entecavir as primary treatment for Chronic Hepatitis B
PP-198 SA00888 Yan Chang Lei A recombinant HBV vector mediated liver specfic anti-HBV activity of C- terminal truncated pokeweed antiviral protein
PP-199 SA00896 Xinmin Wang The psychological status and life quality of patients with chronic hepatitis B
PP-200 SA00908 Yan Chang Lei Inhibition of Hepatitis B Virus Replication by HumanAPOBEC3 Editing Enzymes containing double cytosine deaminase domain
PP-201 SA00911 Da Mi Lee Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients
PP-202 SA00917 Yuexin Zhang nucleosides analog can improve the prognosis of chronic severe hepatitis B patients in short-term
PP-203 SA00920 Xinjian Fan Research on anti-HBV activities of four flavonoids from Halenia elliptica D. Don
PP-204 SA00922 Rintaro Mikata De novo hepatitis B virus (HBV)-related hepatitis after allogeneic hematopoietic stem cell transplantation
PP-205 SA00926 LI Hua Sun Clinical study of adeforvir dipivoxil treatment for HBeAg-positive patients with chronic hepatitis B for 4 years
PP-206 SA00929 Xiao Tang Fan Subsequent therapy for chronic hepatitis B patients following Lamivudine initial no response
PP-207 SA00936 Padaki Nagaraja Rao Efficacy of Entecavir in Chronic Hepatitis B Liver Disease Patients- A Prospective Observational Study
PP-208 SA00939 P Marcellin Large International, Observational Study of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40KD] (PEGASYS): the S-collate Cohort
PP-209 SA00949 P Marcellin On-Treatment Decline in Serum HBsAg Levels Predicts Sustained Immune Control 1 Year Post-Treatment and Subsequent HBsAg Clearance in HBeAg-Negative Hepatitis B Virus-Infected Patients Treated With Peginterferon Alfa-2a [40KD] (PEGASYS)
PP-210 SA00960 T Piratvisuth Sustained Immune Control 1 Year Post-Treatment With Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated With a High Rate of HBsAg Clearance in HBeAg-Negative Chronic Hepatitis B
PP-211 SA00970 T Piratvisuth On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months post-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS)
PP-212 SA00991 Lin Qing E.A.C.H.:Entecavir(ETV) versus Adefovir(ADV) for Patients with Chronic Hepatitis B :Therapy for 48 weeks
PP-213 SA00993 Hui Wang Virologic Efficacy Of Peginterferon α-2a Therapy In Chronic Hepatitis B Patients With Persistently Normal ALT Levels
PP-214 SA01047 Yida Yang Dynamic analysis of CD127 expression on the memory CD8 T cells from chronic hepatitis B patients treated with peginterferon α-2a
PP-215 SA01101 Minning Song Adefovir treatment of chronic hepatitis B 3-year observation of clinical efficacy and drug resistance
PP-216 SA01116 Ming-Juan Yuan Lamivudine efficacy on the prevention and treatment of hepatitis B virus reactivation induced by glucocorticoid in the patients with HBV infection
PP-217 SA01125 Mamun Mahtab Sequential Treatment of Children with CHB in Immunotolerant Phase with Lamivudine and Interferon
PP-218 SA01129 Mamun Mahtab Antiviral Potentiality of a Combination Therapy (Antiviral and Immune Therapy) in Incidentally-Detected Chronic Hepatitis B Virus-Infected Subjects (IDHAS) in Bangladesh
PP-219 SA01143 Minghua Qi Changing of HBVDNA and HBeAg in HbeAg(+) patients with Ldt Treatment
PP-220 SA01165 Cai QingXian A meta-analysis of the treatment of severe chronic hepatitis B with lamivudine
PP-221 SA01180 Li-Chun Wang Lamivudine plus adefovir dipivoxil versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients
PP-222 SA01184 Weixia Liu Establishment of Cell Lines Secreting preS2-TLM-ScFv Fusion Protein Targeted Translocating into HBsAg Expressed Cells
PP-223 SA01189 Pauli Virtanen Electron transfer in therapeutic alkaloids triggers anastomoses in traumatized liver blood flow.
PP-224 SA01192 Jie Yusheng A 96-weeks study of antiviral therapy for patients with HBeAg-negative cirrhosis
PP-225 SA01227 Liang Peng Efficiency of recombinant yeast hepatitis B vaccination in neonates from South of China
PP-226 SA01232 Nancy Leung Changing experience of antiviral therapy for chronic hepatitis B patients in Hong Kong
PP-227 SA01241 Andrea Marengo 8 YEARS OF LAMIVUDINE (LAM) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN A SINGLE CENTER: LONG-TERM RESPONDERS IN A RETROSPECTIVE ANALYSIS
PP-228 SA01263 Bian Zhong-Qi siRNA Targeting HBV Gene Inhibits Hepatitis B Virus Expression and Replication in BHK-21 Cells
PP-229 SA01294 Shiwu Ma The Dynamics of CD8 Lymphocyte TCR Spectratypes Perturbation Associated with Virological Response in CHB Patients Treated with Nucleot(s)ide Analogues
PP-230 SA01302 Fang-Qin Li Preliminary clinical study of anti-HBV-DC combine Thymosin-a1 treating the HBeAg negative chronic hepatitis B patients
PP-231 SA01325 Wen-Bao Zhu Preliminary clinical study of anti-HBV-DC combine Thymosin-a1 treating the inactive HBsAg carrier
PP-232 SA01341 Seng Gee Lim Low Risk Of Multiresistant HBV In A Followup Study Of Lamivudine With Adefovir Switch Strategy
PP-233 SA01348 Seng Gee Lim Outcomes Of Treatment For Chronic Hepatitis B Cirrhosis On Lamivudine-Adefovir Therapy
PP-234 SA01349 Jin Qinglong Effect of Lamivudine and Telbivudine on creatine kinase in hepatitis B antiviral treatment
PP-235 SA01363 Yan-fang Jiang Interleukin-33 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice
PP-236 SA01377 Jun-qi Niu The increased expression of 2B4(CD244) on natural killer cells in chronic hepatitis B patients treated with Telbivudine
PP-237 SA01408 Jiang-Ying Yang Preliminary clinical study of anti-HBV-DC combine lamivudine and Thymosin-a1 treating the chronic hepatitis B virus carriers
PP-238 SA01425 Stephan Kaiser Telbivudine Add-on Therapy in an HBeAg-Negative Cirrhotic Patient With a Suboptimal Response to Tenofovir
PP-239 SA01441 Sheikh Mohammad Fazle Akbar A therapeutic nasal vaccine containing both HBsAg and HBcAg was safe, had antiviral potential and induced antigen-specific immunity in patients with chronic hepatitis B
PP-240 SA01445 Sheikh Mohammad Fazle Akbar Mechanism of restoration of immune responses of chronic hepatitis B patients during lamivudine therapy: increased antigen processing and presentation by dendritic cells
PP-241 SA01458 Byung Chul Yoo A Comparison of 12 months and 24 months Treatment Efficacy between Clevudine and Entecavir Therapy for Chronic Hepatitis B
PP-242 SA01468 Yongyan Chen Adjuvant effects of IL-12 on HBV vaccination in mouse models
PP-243 SA01474 Pochamana Phisalprapa HBeAg index as an early predictor of response in chronic hepatitis B, HBeAg positive patients treated with pegylated interferon
PP-244 SA01497 Megan Crane Decline in HBV-specific CD4+ T cells following initiation of nucleoside reverse transcriptase (NRTI) therapy for chronic hepatitis B virus (HBV) infection
PP-245 SA01498 Min Seub Kwac Efficacy of 48 weeks entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir
PP-246 SA01524 Nikhil Patel Tenofovir rescue therapy for patients with viral resistance to Lamivudine and/or Adefovir treatment
PP-247 SA01541 Jong Eun Yeon Three year treatment of Adefovir (ADV) mono- vs. ADV & lamivudine (LMV) combination in HBeAg positive LMV resistant chronic hepatitis B patients
PP-248 SA01561 Nikhil Patel Comparing efficacy and safety of Lamuviduine + Tenofovir and Telbivudine + Tenofovir regimen for primary treatment failure in HBV infection
PP-249 SA01576 Yao Xie HBsAg Clearance And Seroconversion After Treatment With PEGASYS In Chronic Hepatitis B Virus-infected Patients With Low Serum HBsAg Level And Undetectable HBV DNA
PP-250 SA01582 Ronglong Jiang Efficacy and Safety of Peginterferon Alfa-2a in HBeAg-positive Chronic Hepatitis B Patients with ALT Levels >10 Times Upper Limit of Normal
PP-251 SA01590 S.S. Zhu Evaluation of Safety and Efficacy of Extended Pegainterferon-α-2a Therapy in Children with HBeAg-positive Chronic Hepatitis B
PP-252 SA01592 S.S. Zhu Evaluation of the Effect of Extended Peginterferon-α-2a Therapy on Physical and Psychological Development in Children with HBeAg-positive Chronic Hepatitis B
PP-253 SA01600 Mustafa Yakut LONG-TERM RESULTS OF LAMIVUDINE TREATMENT IN PATIENTS WITH ANTI HBe POSITIVE CHRONIC HEPATITIS B.
PP-254 SA01624 Han Jak Ryu Rescue efficacy of lamivudine and adefovir compared to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B
PP-255 SA01641 Joon Suk Kim HBsAg Titer Were More Efficiently Reduced by Clevudine in Patients with Cirrhosis than Those without Cirrhosis.
PP-256 SA01656 Han Jak Ryu Comparision of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV
PP-257 SA01671 Hyun Young Woo A prospective randomized comparison of 96 weeks treatment efficacy between entecavir and adefovir in treatment naïve patients with chronic hepatitis B
PP-258 SA01702 Peng Hu LONG-TERM KINETICS OF HEPATITIS B VIRUS DNA LOAD DURING ADEFOVIR DIPIVOXIL TREATMENT IN NAÏVE PATIENTS
PP-259 SA01732 Young Eun Chon Partial virological response to entecavir in treatment-naive chronic hepatitis B: an evaluation of EASL guideline
PP-260 SA01733 Eugen Dumitru HBV related complications in HIV positive patients during HAART therapy
PP-261 SA01755 Chen Wen Nucleotide analogues can satisfactory inhibit HBV replication of HBeAg-negative chronic hepatitis B patients with ALT＜2×ULN
PP-262 SA01766 Ke Fan The study about the reasons of bad dependence of HBV patients
PP-263 SA01772 Laura Belloni Intrahepatic HBV status after 10 year of sustained viral suppresion by LAM: analysis of cccDNA sequence and expression.
PP-264 SA01790 Jiangbin Wang Antiviral efficacy and hepatic function improvement after 96 weeks entecavir treatment in nucleos(t)ide naive Chinese cirrhotic patients with chronic hepatitis B infection
PP-265 SA01813 J. Sollano Pretreatment Characteristics of Patients With Chronic Hepatitis B in the Philippines
PP-266 SA01823 Nancy Leung Efficacy and Safety of entecavir (ETV) versus adefovir (ADV) in chronic hepatitis B (CHB) patients with evidence of hepatic decompensation
PP-267 SA01824 Young-Oh Kwon Antiviral effects and safety of entecavir (ETV) versus lamivudine (LVD) in HBeAg-negative Korean chronic hepatitis B (CHB) patients: week 48 interim analysis
top
Poster Presentations: Hepatitis C
Presentation No. Submission No. Presenting Author Title
PP-268 SA00303 Yasir Waheed Risk factors and knowledge associated HBV/HCV transmission among the barbers community of Pakistan
PP-269 SA00333 Jia-ji Jiang A community based molecule epidemiology of hepatitis C virus in Fujian province of China
PP-270 SA00665 Weidong Zhang Impact of HIV-1 infection on the prognosis in HCV-HIV-1 co-infected Former Blood Donors
PP-271 SA00700 Raimonds Simanis Chronic Hepatitis C Patient’s Perception on Routes of Transmission of Hepatitis C Virus
PP-272 SA00730 Tsatsralt-Od Bira High Prevalence of Dual or Triple Infection of Hepatitis B, C, and Delta Viruses  Among Patients With Chronic Liver Disease in Mongolia
PP-273 SA01178 Rino Gani Sexual Behavior Determine Heterosexual Transmission of Hepatitis C Virus in HCV-HIV Co-infection Patient.
PP-274 SA01324 Lijun Liu Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in China
PP-275 SA01521 Nikhil  Patel CHANGING SPECTRUM OF HEPATITIS C VIRUS INFECTION IN WESTERN INDIA
PP-276 SA01522 Jung Woo Shin The Impacts of Occult HBV Infection in Serum or Liver Tissue on Treatment Response of Chronic Hepatitis C in Korea
PP-277 SA01668 Kenneth Yan Retrospective Analysis of Pan Asian Outcome of Response to Therapy for Hepatitis C - A Multicenter Study (REPORT-C study)
PP-278 SA01507 Shuang Meng A novel real-time multiplex reverse transcriptase-polymerase chain reaction for the detection of HCV RNA using the armored RNA as internal control
PP-279 SA00204 Farahnaz Jokar Distribution of HCV Genotypes in Hemodialysis Patients in Guilan, North Province of Iran
PP-280 SA00367 Aly  Soliman DISCOVERY OF THE MISSED LINK BETWEEN SCHISTOSOMIASIS AND HCV INFECTION
PP-281 SA00373 Hoda Abd el moety FIBROSURE,APRI  AND FORNS SCORE VERSUS LIVER BIOPSY IN CHRONIC HCV INFECTION IN   EGYPT.
PP-282 SA00423 Katsuharu Hirano Evaluation of the liver stiffness using transient elastography during peg-interferon alpha -2b and ribavirin combination therapy in patients with chronic hepatitis C.
PP-283 SA00536 Muhammad Umar Histological Outcome of Liver Biopsies in Patients With Chronic Hepatitis C- A Local Experience
PP-284 SA00765 Sayabold Batmunkh Introduction of HCV quantification as a diagnostic tool in Mongolia: it’s significance and lessons learned.
PP-285 SA00828 Shahzad Nasr Esfahani Development of a new method for diagnosis of Hepatitis C virus infection by reverse transcription-loop-mediated isothermal amplification
PP-286 SA01208 Naglaa Allam  Study of Iron, Copper and Alpha-1 Antitrypsin In Egyptian Patients With Chronic Hepatitis C
PP-287 SA01808 Ke Fan The research about the condition of chronic hepatitis C patients with liver cirrhosis
PP-288 SA00104 Narina Sargsyants Predominant genotype of hepatitis C virus in Armenia
PP-289 SA00166 Kuo-Chih Tseng Effect of Human Leukocyte Antigen Class I and II alleles on Hepatitis C viral load among Chronic Hepatitis C Patients in Southern Taiwan
PP-290 SA00399 Qiang Liu Hepatitis C virus genotype-3a NS5A protein activates sterol regulatory element-binding protein-1 and fatty acid synthase
PP-291 SA00484 Shingo Nakamoto THE EFFECTS OF HEPATITIS C VIRUS GENOTYPE 1B CORE AMINO ACID SUBSTITUTIONS AT POSITIONS 70 AND 91 ON INTERFERON AND CYTOKINE-RELATED SIGNALING PATHWAY IN HUMAN HEPATOMA CELLS
PP-292 SA00508 Cai Rentian Dynamic expression of  PD-1 in  T cell and clinic significance in chronic hepatitis C patients
PP-293 SA00607 Ri Sho Expression Profiling of TLR Signaling Pathway Genes in Human Hepatocytes Infected with Cell Culture-Produced Hepatitis C Virus
PP-294 SA00681 Qiang Ma A vaccinia replication system for producing recombinant hepatitis C virus
PP-295 SA01666 Nyamdavaa Tuul MD, PhD Prevalence of porphyria cutanea tarda in hepatitis C virus  infection in Mongolia
PP-296 SA01697 Chung-Feng Huang The characteristics of serum visfatin level in patients with chronic hepatitis C virus infection-implications of virology and glucose abnormalities
PP-297 SA00018 Liudmila Palgova DEBUT OF SYSTEM SCLERODERMITIS SECONDARY TO HEPATITIS C ANTIVIRAL THERAPY
PP-298 SA00019 Liudmila Palgova Results of combined antiviral therapy HCV Infection of by peginterferon alpha- 2a and ribavirin in the Republic of Kazakhstan.
PP-299 SA00124 Shaban R. Abdulsalam Bagar PREVALENCE OF HEPATITIS C VIRUS AMONG PATIENTS ATTENDING IBN-SINA HOSPITAL IN SIRT, LIBYA
PP-300 SA00173 Run-Xuan Shao Hepatitis C Virus Replication Induce NF Kappa B System Activation
PP-301 SA00175 Run–Xuan Shao SOCS3 Suppresses HCV Replication in an mTOR-dependent Manner
PP-302 SA00554 Mohamed Hadzri Hasmoni Hepatitis C Genotyping in Haemodialysis Patients and the Development of Genotyping Method Based on TaqMan Probe Real-Time PCR
PP-303 SA00565 Chang Kuo-Chin Prediction of viremia of hepatitis C virus (HCV) infection using a third generation anti-HCV enzyme immunoassay test in hemodialysis patients
PP-304 SA00938 Rathindra mohan Mukherjee Spectrum of Incidentally Detected Hepatitis C Virus Infection in  Southern India- A Prospective Study
PP-305 SA01074 Nauman Arif Jadoon Impact of Hepatitis C Virus Infection On Glycemic Control and Lipid Profiles Of Diabetic Patients
PP-306 SA01097 Srunthron  Akkarathamrongsin Prevalence and Genotypes of Hepatitis C Virus in Migrant Workers from Cambodia, Laos and Myanmar in Thailand
PP-307 SA01179 Rino  Gani Attenuation of Necroinflammation and Fibrosis in HCV – HIV Co-infection Patients with Severe Immunodeficient
PP-308 SA01251 Om Parkash What matters in a liver biopsy core specimen in chronic hepatitis C : the size or number of portal tract! A cross sectional study at tertiary care hospital.
PP-309 SA01358 Lixin Zhang Hepatitis C virus genotypes in Shandong province: The prevalence and clinical significance
PP-310 SA01699 Subhash Medhi Expression Of Toll-Like Receptor-3 (TLR3) And Mitochondrial Antiviral Signaling Protein (MAVS) In Naive And Anti-Viral Therapy Receiving Patients With Chronic Hepatitis C Virus Infection
PP-311 SA00153 Malgorzata Pawlowska Pegylated interferon alpha-2a and ribavirin in the treatment of children with Chronic Hepatitis C.
PP-312 SA00312 Koichi Takaguchi An Innovation of the Hepatitis C Therapy for the Patients Refractory to Pegylated Interferon alfa-2b / Ribavirin Combination Therapy : Combination use of Interferon-beta with Double Filtration Plasmapheresis
PP-313 SA00418 Yeong Jin Song Tailored therapy for treatment-naive chronic hepatitis C with pegylated Interferon alfa and Ribavirin: real practice experience
PP-314 SA00429 Byung Jin Choi 24weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia.
PP-315 SA00465 Qiuxia Fu Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals
PP-316 SA00870 Daisuke Maruoka Prognosis of Chronic Hepatitis C After Interferon Therapy by Long-Term Cohort Study
PP-317 SA00894 SeokHyun Kim Relapse rate after pegylated interferon alpha 2a and ribavirin therapy in patients with chronic hepatitis C
PP-318 SA01161 Li Duan Prediction of Chinese hepatitis C virus CTL epitopes and analysis on immunogenicity of multi-epitopes antigen gene
PP-319 Offline 3 Claudio Pasquinelli Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single and Multiple-dose Administration of BMS-650032, a novel HCV NS3 Inhibitor, in subjects with Chronic Genotype 1 HCV Infection
PP-320 Offline 4 Andrew J Muir A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-IFN-λ) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
PP-321 Offline 5 R.E.Nettles BMS-790052 is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study
PP-322 SA00096 Jian-Wu Yu Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
PP-323 SA00102 Chun-Hsiang Wang A Prospective Study Using Artificial Neural Network Model Based On Single Nucleotide Polymorphisms And Other Clinical Factors To Predict Therapeutic Response Of Combined Pegylated Interferon And Ribavirin In Patients With Chronic Hepatitis C  
PP-324 SA00105 Narina Sargsyants Comparison of liver function tests in responders and non-responders of the treatment with PEG Interferon Alfa 2a plus ribavirin in chronic hepatitis C
PP-325 SA00106 Mohan Kumar Long term sustain viral response in chronic hepatitis c relapser patients with peg inerferone who relapse after conventional interferone thearpy in northern area of pakistan
PP-326 SA00142 Vasileios Papadopoulos Should active injecting drug users receive treatment for chronic hepatitis C?
PP-327 SA00152 Gulnara Aghayeva Diabetes mellitus and Insulin resistance in hepatitis C patients.
PP-328 SA00232 Mamun Mahtab Estimation of Insulin Resistance in Patients with Hepatitis B and Hepatitis C Virus Related Chronic Liver Disease
PP-329 SA00324 Eduardo Vilar Gomez Antioxidant and immunomodulator effect of Viusid ® in patients with chronic hepatitis C: a double-blind, placebo-controlled study.
PP-330 SA00340 Ronglin Zheng Interferon-2a decreases expression of TBC1D20, a possible cofactor involved in the replication of HCV in hepatocytes
PP-331 SA00409 Manal El-Hamamsy The impact of serum autoantibodies among  chronic hepatitis C genotype 4(HCV) patients  attending a national center of HCV treatment program in Egypt
PP-332 SA00437 Gamal Shiha Efficacy of new PEG-Interferon α- 2a (Reiferon Retard®) plus Ribavirin in Egyption Patients with Chronic Hepatitis C
PP-333 SA00477 Muzzaffar Gill OUTCOMES OF CONSEUS INTERFERON AND RIBA THERAPY FOR CHRONIC HEP C G3 PATIENTS WHO RELAPSED WITH PREVIOUS PEG-INTERFERON AND RIBA THERAPY
PP-334 SA00493 Rika Ishii Occurrence of hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C
PP-335 SA00503 Patrick Marcellin Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) has a wide safety margin in patients infected with HCV genotype 1
PP-336 SA00504 Maribel Rodriguez-Torres Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) for chronic hepatitis C (CHC) in HIV-HCV co-infected patients: final results of the PARADIGM study
PP-337 SA00533 Muhammad Umar Effectiveness of 24 weeks combination therapy for treatment of Hepatitis- C
PP-338 SA00577 Gill Muzzaffar RAPID VIROLOGICAL RESPONSE IS A  PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEP C G3 PATIENTS TREATED WITH PEGASYS AND RIBAVIRIN
PP-339 SA00579 Muzzaffar Gill OUTCOMES OF CHRONIC HEPC G3 CIRRHOTICS TREATED WITH PEGINTRON AND RIBAVIRIN  
PP-340 SA00594 Doha Taie Hepatocyte Growth Factor Activator In Liver Biopsies of Egyptian Patients with Hepatitis C Virus-Related Chronic Hepatitis: Correlation With Hepatic Repair
PP-341 SA00599 Tadashi Goto Prospective Randomized Controlled “Head to Head” Trial of Peginterferon alpha-2a Versus Peginterferon alpha-2b in Combination With Ribavirin (IHIT-II) Study. The Second Report.
PP-342 SA00679 Masayuki Kurosaki Impact of Mutations in ISDR and Core Region of HCV on Pretreatment Prediction of Sustained Virological Response to Pegylated-interferon Plus Ribavirin Therapy Revealed by Classification and Regression Tree Analysis
PP-343 SA00688 I Shyan Sheen SPLENECTOMY WITH SUBSEQUENT ANTIVIRAL TREATMENT IS BENEFICIAL FOR HEPATITIS C, COMPENSATED CIRRHOTICS WITH THROMBOCYTOPENIA
PP-344 SA00715 Dong Hyun Sinn Efficacy of the Currently Recommended Ribavirin Dose in Koreans: Need for Reassessment of Ribavirin Dosing Regimen
PP-345 SA00725 Naglaa Allam Interferon-induced thyroid dysfunction in chronic hepatitis C in the Middle East
PP-346 SA00726 SH Park Efficacy and tolerability of peginterferon alfa plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea; a multi-center, retrospective observational study
PP-347 SA00754 S Pianko Final results of ACHIEVE-1: albinterferon alfa-2b plus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C
PP-348 SA00762 W-L Chuang Final results of ACHIEVE-2/3: albinterferon alfa-2b plus ribavirin in treatment-naïve patients with genotype 2/3 chronic hepatitis C
PP-349 SA00778 Akio Miyasaka Efficacy of short term treatment with interferon-beta in patients with hepatitis C virus serotype 2 and low viral load
PP-350 SA00805 Eugen Georgescu FLUVASTATIN IMPROVES EARLY (EVR) AND SUSTAINED (SVR) VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON AND RIBAVIRIN. A PRELIMINARY STUDY.
PP-351 SA00819 YONGHONG ZHANG The contribution of HCV specific immunity to the control of disease progression in chronic HCV infection in China
PP-352 SA00885 Zaigham Abbas A randomized trial of Interferon Alpha, ribavirin plus interferon gamma or amantadine for HCV Genotype 3 non-responders and relapsers
PP-353 SA00951 Qing Xie Changes in microRNA expression profiles in HCV replicon-containing cell lines by IFN-β and ribavirin combination therapy.
PP-354 SA01002 Peter Ferenci Baseline characteristics and interim on-treatment responses from the real-world PROPHESYS cohorts inform future treatment paradigms for chronic hepatitis C (CHC)
PP-355 SA01003 Darrell H. Crawford Predicting SVR by combining early measurements of viral load with baseline characteristics including fibrosis score: Enhanced potential to individualize HCV treatment decisions
PP-356 SA01004 Samuel S. Lee Predictors of discontinuation and dose reduction in patients with chronic hepatitis C treated with peginterferon alfa-2a (40KD) plus ribavirin in a multinational open-label expanded access program
PP-357 SA01094 Gamal Shiha Efficacy of new PEG-Interferon α- 2a (Reiferon Retard®) plus Ribavirin in Egyption Patients with Chronic Hepatitis C
PP-358 SA01119 Kenneth KL Yan Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital
PP-359 SA01164 Phil McEwan A Need for a Dynamic Approach to Modelling Disease Progression in Cost-Effectiveness Studies of Antiviral Therapies in Patients with Chronic Hepatitis C.
PP-360 SA01166 Xuezhong Lei Treatment of Chinese patients with chronic hepatitis C with peginterferon alfa-2a (40KD) plus ribavirin (RBV)
PP-361 SA01211 Alyaa Sabry  Evaluation of Egyptian patients with chronic hepatitis C Genotype 4 with persistently normal ALT including response to antiviral therapy
PP-362 SA01230 CJ Liu Peginterferon alfa plus Ribavirin for 24 or 48 weeks in Genotype 1 Chronic Hepatitis C Patients in Taiwan
PP-363 SA01297 Dominique Larrey Nurse-provided therapeutic education in patients with chronic hepatitis C treated by Peg-Interferon-alpha2a-Ribavirin : impact on quality of life
PP-364 SA01301 Yoshiaki Iwasaki A Response-Guided-Therapy is Feasible in Peginterferon plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients with Genotype 1 and Amino Acid Substitutions in the Core Region
PP-365 SA01315 Yi Zhang Transfer of Hepatitis C virus (HCV)-reactive T cell specificity for the treatment of HCV-associated hepatocellular carcinoma
PP-366 SA01416 Masroor Qazi EFFECT OF DIABETES MELLITUS (DM) ON THE EFFICACY OF STANDARD INTERFERON (SdIF) PLUS RIBAVIRIN COMBINATION THERAPY IN PATIENTS OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE-3
PP-367 SA01430 Chia-Yen Dai Pegylated interferon/ribavirin therapy for chronic hepatitis C patients who did not response to previous conventional interferon/ribavirin therapy
PP-368 SA01558 Khin May  Oo Preliminary findings on the effectiveness of heat-treated Enterococcus faecalis FK-23 preparation in the management of hepatitis C carriers 
PP-369 SA01591 Soo Young Park Clinical outcome of pegylated interferon plus ribavirin combination therapy for chronic hepatitis C virus infection in Korea
PP-370 SA01602 Mustafa Yakut Long Term Follow-Up For The Patients Treated With Pegylated İnterferon Plus Ribavirin For Chronic Hepatitis C
PP-371 SA01659 Nai-Jen Hou Stem cell transplantation for leukemia patients from chronic hepatitis C donors with and without peginterferon-alfa and ribavirin pretreatment
PP-372 SA01663 Makoto Kuboki Prevalence and therapeutic significance of neutralizing anti-interferon antibodies to interferon alpha among chronic hepatitis C patients non-responder to peginterferon alpha 2a.
PP-373 SA01670 Necati Ormeci A prospective study to evaluate the prognostic value of Fibrotest, a non-invasive fibrosis markers, for predicting liver fibrosis and the efficacy of peginterferon treatment on fibrosis formation in patients with chronic HBV infection.
PP-374 SA01680 P. Patrick  Basu Effect of High-Dose Ribavirin (RBV), Alinia (Nitazoxanide) and Pegylated Interferon (PegIFN) alfa-2a in attaining Sustained Virologic Response (SVR) in Treatment of Chronic Hepatitis C (ERAIS-C Trial) in Naïve Genotype 1 Patients
PP-375 SA01682 Shih-Jer Hsu EARLY VIRAL KINETICS PREDICTS VIROLOGIC RESPONSES TO PEGINTERFERON PLUS RIBAVIRIN TREATMENT IN TAIWANESE PATIENTS WITH CHRONIC HEPATITIS C
PP-376 SA01688 Xiaoyuan Xu Abnormal glycometabolism in Chronic Hepatitis C: Insulin resistance impairs rapid virologic response
PP-377 SA01712 Cristina Cijevschi Prelipcean How can we influence the sustained viral response in patients with chronic hepatitis C and diabetes mellitus?
PP-378 SA01764 Saleem Bokhari Scientific Validation of an Efficient Herbal Formulation Against Hepatitis C
PP-379 SA01804 Masaru Ogasawara Effectiveness of Double Filtration Plasmapheresis for Hepatitis C Virus Genotype 1b Patients with High Viral Load.
PP-380 SA01826 Ahmet Uyanikoglu DURABILITY OF SUSTAINED VIRAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C
PP-381 SA01838 Claudio Pasquinelli Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single and Multiple-dose Administration of BMS-650032, a novel HCV NS3 Inhibitor, in subjects with Chronic Genotype 1 HCV Infection
PP-382 SA01839 AJ Muir A Phase 1b Dose-Ranging Study of 4 weeks of Peg-Interferon (IFN) Lambda (Peg-IFN-λ) in combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
top
Poster Presentations: Other Viral Hepatitis
Presentation No. Submission No. Presenting Author Title
PP-383 SA00242 Jibao Geng HEV genotype and the prevalence of anti-HEV in 8 species of animals
PP-384 SA01353 Jaejun Shim Epidemiological change of acute hepatitis A in recent 13 years: a single center experience in Korea
PP-385 SA01644 Jin-Woo Lee 10-year change of Hepatitis A prevalence in a single tertiary care center
PP-386 SA00108 GUANG FU JIAN Effects of Anti-viral Treatment of Chronic Hepatitis B on Clinical Prognosis
PP-387 SA00134 Erwin  Ho Hepatitis B-delta virus co-infection in Belgium:  joint analysis of prospective data of the BASL HDV and HBV registries
PP-388 SA00257 Hongwei Fu Hepatitis E virus infection among animals and human in Xinjiang China: Evidence of swine-to-human transmission of sporadic hepatitis E in disease-endemic region.
PP-389 SA00424 Sudhamshu K.C. Profile of pediatric viral hepatitis in Kathmandu
PP-390 SA00618 Jiabao Geng Evidence of zoonotic transmission of hepatitis E virus (HEV) between human and swine: full genome sequence and analysis of swine HEV
PP-391 SA00675 Zary  Nokhodian :  Is hepatitis A a challenge among Isfahan street children?
PP-392 SA00711 Ho Seong Rew Gestational complications associated with acute hepatitis A in pregnancy
PP-393 SA00712 Sung Kyu Choi Genetic analysis and clinical characterstics of hepatitis A virus from sporadic cases in Gwangju, Korea; 2008-2009
PP-394 SA00735 Baatarkhuu Oidov Prevalence and genotype distribution with hepatitis A, B, C, and Delta viruses among patients with acute viral hepatitis in Mongolia
PP-395 SA00845 Hee Bok Chae Is there any relation between the genotype of Hepatitis A virus and the severity of hepatitis?
PP-396 SA00855 Zaigham Abbas Interferon-alpha for hepatitis D: a systematic review
PP-397 SA00901 LIU Li ZHUANG Lin Long-term observation on progression of acute hepatitis E to Chronic trend
PP-398 SA01088 Xiaojuan Wang Experimental infection of SD rats with swine hepatitis E virus (HEV)
PP-399 SA01288 Su Rin  Shin Clinical characteristics of patients with delayed diagnosis of acute viral hepatitis A
PP-400 SA01654 Sukriti Sukriti HEV Infection Follows DC–Specific Intercellular Adhesion Molecule 3–Grabbing Non integrin (DCSIGN) Rather Than Toll Like Receptor (TLR) Dependant Pathway For Viral Recognition
top
Poster Presentations: Non-alcoholic Fatty Liver Disease (NAFLD)
Presentation No. Submission No. Presenting Author Title
PP-401 SA00431 Zhe Shen Accumulation of liver progenitor cells and the correlation with Hedgehog signaling pathway in mice of MCD diet induced fatty liver
PP-402 SA00789 Makoto Fujimoto Monacolin K and other constituents of red yeast rice are effective against obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis in a mouse model of NAFLD associated with metabolic syndrome
PP-403 SA00841 Koichi Tsuneyama Spirulina and its constituent phycocyanin improve visceral fat macrophage aggregation, serum adiponectin level, and steatohepatitis in a mouse model of NAFLD associated with metabolic syndrome
PP-404 SA01690 Xiao-yan Duan Characterization of a rat model of nonalcoholic steatohepatitis (NASH) with liver tumor: high-fat diet enhances liver tumor formation induced by diethylnitrosamine.
PP-405 SA00036 Ruidan, ZHENG Expression and significance of liver X receptor-α in nonalcoholic fatty liver disease in rats 
PP-406 SA00230 Ying-Bin Hu Protective effects of SP600125 in a diet-induced rat model of nonalcoholic steatohepatitis
PP-407 SA00297 Shi-Ying Xuan Serum Peptidome Patterns In Non-Alcoholic Fatty Liver Disease：A Study In Qingdao Twins
PP-408 SA00366 Ming-Ling  Chang HCV core-induced nonobese hepatic steatosis is associated with hypoleptinemia
PP-409 SA00372 Lamei Xu Changes of intestinal epithelial tight junction and the expression of occludin in non-alcoholic fatty liver disease rats
PP-410 SA00394 Lijing Bao The Effects of Rosiglitazone or Combined with Reduced Glutathione on insulin resistance related indicators in NAFLD rats
PP-411 SA00574 Koichi Tsuneyama TSOD mouse: a new spontaneous model of nonalcoholic steatohepatitis and hepatocellular carcinoma associated with obesity, type 2 diabetes, and hyperlipidemia
PP-412 SA00617 Yue-Min Nan Heme oxygenase-1 prevents experimental non-alcoholic steatohepatitis and hepatic fibrosis in mice
PP-413 SA00763 Yue-Min Nan The role of Fas mutation on nutritional steatohepatitis in mice
PP-414 SA01814 Jian Wu Label-Free Monitoring of Lipid Droplets in Primary Hepatocytes Exposed to Lipolysis Products
PP-415 SA01818 Yu-lin  Song Effect of MEK/ERK signal pathway on the expression of sterol regulatory element binding protein-1 in NAFLD induced by high-fat diet in rats
PP-416 SA00098 Jong In Yang Association of Body Mass Index with Liver Enzyme Concentrations and Metabolic Factors in Korean Population
PP-417 SA00405 YING TIANMING Observation of therapeutic effect of TINMAX Bright Liver (herbal compound) in patients with nonalcoholic fatty liver disease
PP-418 SA00478 Yuko Nishise Relationship between an Increased Bright Echo Pattern of the Liver on Ultrasonography and Metabolic Syndrome in a Japanese Population
PP-419 SA00557 Makoto Fujimoto The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease
PP-420 SA00893 Jeong Han Kim Comparision of Intima-media thickness between Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease
PP-421 SA01337 Yong Kyun  Cho The Change of Insulin Sensitivity in Non-alcoholic fatty liver disease (NAFLD) Patients with Normal insulin sensitivity
PP-422 SA01490 Makoto Suzuki The significance of the LDL/HDL ratio in NAFLD
PP-423 SA00014 Ehab Abdel-Khalek Insulin resistance and serum lipoproteins as differentiating parameters of simple steatosis versus nonalcoholic steatohepatitis
PP-424 SA00168 Azita Hekmatdoost DIET IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS.
PP-425 SA00190 Azita Hekmatdoost Soy protein consumption in patients with NASH: A Crossover, Randomized Clinical Trial.
PP-426 SA00281 Xue-hua Sun The clinical study of ShenGe decoction combined with dietotherapy and kinesitherapy  on Non-alcoholic fatty hepatitis
PP-427 SA00290 Yu-Yuan   Li Natural history and associated risk factors of NAFLD in southern China: A four year follow-up population based study
PP-428 SA00314 Yu-Yuan  Li Epidemiologic features of NAFLD in elderly Chinese: Four year follow-up of subjects undergoing physical check-up
PP-429 SA00317 Yu-Yuan Li The influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease in Chinese people
PP-430 SA00509 Chengfu Xu High serum uric acid as a novel risk factor for nonalcoholic fatty liver disease
PP-431 SA00729 Junping Shi Hyperuricemia   is   associated   with   hepatic steatosis  in  patients  with fatty liver disease ,  but  not  inflammation   and   fibrosis
PP-432 SA00740 Jian Huang A study of the relationship between cardiac diastolic function and liver function in patients with nonalcoholicfatty liver disease
PP-433 SA00857 Yuyuan Li The effect of adiponectin-45 polymorphism on the incidence of NAFLD: A four year follow-up study
PP-434 SA00956 Chunliang Liu Meta-analysis on the association between serum ferritin and non-alcoholic fatty liver disease
PP-435 SA01028 Anand JALIHAL Spectrum of hepatic disorders seen in the Hepatology clinic in RIPAS Hospital, Brunei Darussalam
PP-436 SA01111 Shi-Ying  Xuan Prevalence of and risk factors for fatty liver in an adult  physical examination population of Qingdao, China.
PP-437 SA01145 Kshaunish Das Is there a need to redefine “normal” alanine aminotransferase (ALT) values in healthy asymptomatic individuals?
PP-438 SA01243 Jeong Han Kim Comparision of Carotid Intima-media thickness between Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease
PP-439 SA01466 Kanta Oikawa A clinical and pathological investigation of the risk factors of NASH
PP-440 SA01495 Jae Sung Ko Nonalcoholic Fatty Liver Disease in Children with Hypopituitarism
PP-441 SA01516 Nikhil Patel Non-alcoholic fatty liver disease as a predictor of diabetes
PP-442 SA01585 Jie Sun Prevalence and clinical risk factors of non-alcoholic fatty liver disease among elderly people in Chang Chun city of China
PP-443 SA01651 Jian-gao Fan Incidence and risk factors of non-alcoholic fatty liver disease in Shanghai BaoSteel Group employees
PP-444 SA01704 Yeh Ming-Lun Course of Non-alcoholic steatohepatitis progression: comparing of paired liver biopsy
PP-445 SA01834 Amir Ttaheri Efficacy of Oats Supplementation in Treatment of Nonalcoholic Steatohepatitis
PP-446 SA00138 Noriyuki Obara Impact of trans-fatty acid-rich high fat diet on nonalcoholic fatty liver disease in mice
top
Poster Presentations: Alcoholic Liver Disease
Presentation No. Submission No. Presenting Author Title
PP-447 SA00345 Chengfu Xu Early mortality of alcoholic hepatitis: A review of data from placebo-controlled clinical trials
PP-448 SA00380 Balasubramaniyan  Vairappan Effect of exogenous leptin administration on alcohol induced fibrogenesis and apoptosis in the mouse hepatocellular carcinoma cell lines
PP-449 SA00411 Nadana Saravanan Effect of Hemidesmus indicus and 2-hydroxy 4-methoxy benzoic acid on rat feeding model of ethanol induced hyperlipidemia
PP-450 SA00990 Ping Yao Quercetin enhanced adaptive protection of hemeoxygenase-1 against alcoholic oxidative stress via different MAPK pathway from ethanol
PP-451 SA00994 Jinghua Peng The effects of puerarin on chronic alcoholic liver injury and gut-leakage in rats
PP-452 SA00996 Tuan Cui The effect of Pueraria Flavonid on chronic alcoholic liver injury in rats.
PP-453 SA01157 Hoang Trong Thang THE RELATIONSHIP BETWEEN THE TIME, QUANTITY OF ALCOHOL DRINKING AND THE CHANGES OF LIVER ENZYMES AND CORPUCULE VOLUME
PP-454 SA01346 Monika Bhadauria Resveratrol Ameliorates Hepatic abnormalities induced by Combined Consumption of Alcohol and High Fat Diet: A Molecular Mechanism
PP-455 SA01386 Neelanjana Roy ASSOCIATION OF POLYMORPHIC MARKERS OF SELECTED CANDIDATE GENES IN RELATION TO ALCOHOLIC LIVER DISEASE (ALD) IN INDIA
PP-456 SA01411 Wei Bao Transforming Growth Factor-beta (TGF-beta) Gene Polymorphisms and Susceptibility of Alcoholic Liver Disease: A Meta-Analysis
PP-457 SA01520 Arvind kumar Shakya Evaluation of hepatoprotective efficacy of Majoon-e-dabeed-ul-ward against alcohol induced liver injury in mice
top
Poster Presentations: Metabolic and Genetic Disease
Presentation No. Submission No. Presenting Author Title
PP-458 SA00396 Ramakrishna.  Ch Antioxidant and Hypoglycemic effects of ginger in STZ induced diabetic rats.
PP-459 SA00468 Yuji Iimuro Analysis of liver regeneration pattern after laparoscopic fenestration of liver cysts
PP-460 SA00496 Zhang Peiyi Treatment of polycystic liver diseas with percutaneous injection of acetic acid
PP-461 SA00652 Heon Young  Lee A Case of Concomitant Gilbert’s syndrome and Hereditary spherocytosis
PP-462 SA01234 Xin-Hua Li Comprehensive genotype-phentype study of Wilson’s disease in China
PP-463 SA00133 Feng Wang ATP7B mutation analysis in Wilson disease patients with liver injuries from Northeast China
PP-464 SA00233 Harun-or- Rashid Diabetes Mellitus is the important risk factor for decompensated cirrhosis of liver in Bangladesh-Experience from a tertiary centre.
PP-465 SA00234 Harun-or- Rashid Diabetes Mellitus is the most important cause for delayed recovery & hepatic decompensation of acute viral hepatitis patients in Bangladesh: Experience from a tertiary centre.
PP-466 SA01182 Suk Bae Kim The Positive Interaction of Alcohol, Smoking and Obesity to Serum Gamma-Glutamyltransferase(r-GT)
PP-467 SA01285 Souheil M. Shabib Liver Transplant in Children With Congenital Factor VII Deficiency
PP-468 SA01484 Hu Yulin Clinical features and analysis of 5 cases diagnosed hepatic and renal amyloid degeneration
top
Poster Presentations: Autoimmune Hepatitis and Cholestatic Liver Disease
Presentation No. Submission No. Presenting Author Title
PP-469 SA00169 Azita Hekmatdoost Celiac Disease: The top of an iceberg in patients with hepatitis?
PP-470 SA00400 Kentaro Kikuchi BAFF from monocytes enhances B cell innate immune response in primary biliary cirrhosis
PP-471 SA00507 Yuki Moritoki Anti-CD20 treatment ameliorates autoimmune cholangitis but exacerbates colitis in dnTGF-βRII mice
PP-472 SA00562 Joo Hyun Sohn A Case of Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome in HBV Carrier
PP-473 SA00692 Hong-mei Xu Effect of eomdin on P-gp expression in intrahepatic cholestatic rats
PP-474 SA00695  Hong-mei Xu Effect of emodin on transporter gene expression in intrahepatic cholestatic rats
PP-475 SA00707 Sang Youn  Hwang Clinical Characteristics of Autoimmune Liver Disease in Korea
PP-476 SA00716 Kyung-ah Kim Clinical features and prognosis of primary biliary cirrhosis in Korea
PP-477 SA00743 Qianyi Wang Clinical and Pathological Comparison of Autoimmune Hepatitis and Drug-induced Liver Disease in China
PP-478 SA00933 Xiong Ma Validation of the Simplified Criteria for Diagnosis of Autoimmune Hepatitis in Chinese Patients
PP-479 SA00937 Xiong Ma Crosstalk between Th17 cells and Hepatocytes through a positive feedback loop of Interleukin-17 and Interleukin-6 expression in autoimmune hepatitis
PP-480 SA00950 Ding kang Yao Proteomic analysis of serum and tissue by isotope labeling relative and absolute quantification in primary biliary cirrhosis mice.
PP-481 SA00999 Kaiyu Zhang Detection and clinical significance of anti-mitochondrial antibodies for autoimmune liver disease
PP-482 SA01080 Norwani BASIR Autoimmune hepatitis in children in Brunei Darussalam
PP-483 SA01086 Hiroki TAKAHASHI Serum level of pro-inflammatory adipokine Visfatin reflects the disease activities of autoimmune liver diseases.
PP-484 SA01193 Shin Yasui CT imaging features of acute onset autoimmune hepatitis
PP-485 SA01202 Atsushi Tanaka A novel health-related quality of life questionnaire specific for primary biliary cirrhosis ‘PBC-27’; validation in Italian and Japanese
PP-486 SA01378 Jun-qi Niu Analysis of immune activation and clinical events in Autoimmune hepatitis patients
PP-487 SA01470 Zhigang Tian Innate Immune Receptors-Mediated Liver injury: A Summary Study
PP-488 SA01674 Lingjuan Fang Cholestatic Liver Disease in a Chinese Patient with a Homozygous Mutation in the 3β-hydroxy-C27-steroid dehydrogenase gene
top
Poster Presentations: Drug Induced Liver Disease (DILD)
Presentation No. Submission No. Presenting Author Title
PP-489 SA01730 Peng Hu Clinical features of 108 patients with drug-induced liver diseas
PP-490 SA00074 Xiong Zhao The effects of tamoxifen on insulin sensitivity in L02 hepatic cells .
PP-491 SA00296 Won Kim Anti-tuberculous drug-induced hepatotoxicity in chronic hepatitis versus cirrhosis
PP-492 SA00591 Wang Xiao-jin Drug-induced liver injury related with Zhixue Capsules: An analysis of  30 gregarious patients
PP-493 SA00833 Adeline Lim Hepatoprotective Effect of Sunitinib in a Paracetamol Toxicity Mice Model
PP-494 SA00843 Yaping  HAN Care Strategies for Patients with Severe Drug-Induced Hepatitis
PP-495 SA00849 Yanying Zhao Diagnosis, treatment and follow-up of 6 patients with drug for treatment of hemorrhoids-induced cholestatic hepatitis in Shenzhen Shekou people's Hospital
PP-496 SA00875 Yanying Zhao Diagnosis, treatment and follow-up of 6 patients with drug for treatment of hemorrhoids-induced cholestatic hepatitis in Shenzhen Shekou people's Hospital
PP-497 SA00978 CHengwei Chen More Attention Should be Paid to Drug-Induced Liver Disease
PP-498 SA01171 Adnan Bajraktarevic DRUG INDUCED LIVER INJURY IN CHILDREN
PP-499 SA01343 NEETU SHARMA Hepatoprotective effect of aqueous extract of Butea monosperma flowers on acetaminophen induced liver damage
PP-500 SA01696 HONGCHANG CHOU Evaluation 152 Patients in Drug Induced Liver Injury with Antinuclear Antibody Positive or Negative
top
Poster Presentations: Liver Fibrosis
Presentation No. Submission No. Presenting Author Title
PP-501 SA00132 Naoki Uyama Fascin, an actin bundling protein, may regulate functions of hepaticstellate cells through FAK-PI3K-Akt pathway
PP-502 SA00151 Yoichi Yasuda (–)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRβ and IGF-1R
PP-503 SA00213 Canjie Guo Signaling pathways involved in hepatic stellate cell activation are regulated by miRNAs
PP-504 SA00486 Hu Guo-xin Effects of hydroxycamptothecin on the proliferation and apoptosis of rat hepatic stellate cells in vitro
PP-505 SA00684 Jia-ji Jiang The effects of TGF-β1 on the mesenchymal stem cells transplantation on hepatic fibrogenesis and hepatoma in rats
PP-506 SA00709 R.P. Gao Connective tissue growth factor expression and its role in HBV-induced liver fibrosis
PP-507 SA00091 Olav A Gressner Connective Tissue Growth Factor is an interleukin-6/ STAT3-regulated hepatic negative acute phase protein
PP-508 SA00154 Sun Jung Myung Exisulind attenuates hepatic stellate cell activation and survival through JNK and nuclear factor kappa B-dependent mechanism
PP-509 SA00185 Xin Tong Changes of hepatic proteome in DMN-induced cirrhosis/fibrosis and the effects of Huangqi Tang intervention in rats
PP-510 SA00304 Xu Li Upregulation Of Angiotensin Converting Enzyme 2 In Hepatic Fibrosis By
PP-511 SA00306 Hongdong Xie Proteomic Analysis of the Effect of FuZhengHuaYu Recipe on Fibrotic Liver in Rats
PP-512 SA00520 Li  Wenting Pokeweed antiviral protein (PAP) attenuates liver fibrosis through inhibiting Wnt/β-catenin pathway.
PP-513 SA00578 Zhan Zhang A study on Salidroside inhibits migration of hepatic stellate cell line
PP-514 SA00637 Yingdi Liu Leptin potentiates acetaldehyde-induced activation of hepatic stellate cells in vitro
PP-515 SA00659 Yanfeng  Bai Suppression of tissue inhibitor of metalloproteinase-1 (TIMP-1) by recombinant lenti-virus carrying small interfering RNA in hepatic stellate cells
PP-516 SA00796 Yu-Ping  Wang Effects of Blueberry on Hepatic Fibrosis and Phase ⅡEnzymes in Rats
PP-517 SA00800 Yu-ping Wang Expression of HO-1 in Rat hepatic fibrosis and the effect of Blueberry on its expression pattern
PP-518 SA00854 Dingzhu Shen  Effect mechanism of CK8, CK18 and TCTP in a rat model of hepatic fibrosis induced by CCl4
PP-519 SA00856 Ming-Kuei Tsai Effects of salvianolic acids in platelet-derived growth factor-induced cell signaling via p70 S6 kinase in rat hepatic stellate cells
PP-520 SA00867 Ting-Fang Lee In vitro and in vivo studies of kaerophyllin against hepatic fibrosis in rats
PP-521 SA00882 Bingfeng Qiu Transdifferentiation of hepatocytes mediated by TGF-β1 autocrined in hepatocytes after bile duck ligation rats
PP-522 SA00890 Ching-Fen  Wu Hepatitis C virus core protein induces oxidative stress and hepatic fibrogenesis
PP-523 SA00910 Hangping Yao Enhanced effect of soluble transforming growth factor-β receptor II and IFN-γ fusion protein in reversing hepatic fibrosis
PP-524 SA00916 Bibigul Ilyassova The signal molecules of autoimmunity in the pathogensis of liver cirrhosis caused by chronic hepatitis B
PP-525 SA00962 Zhen Zeng Effect of Xiaozhang Cataplasm on ascites and gastrointestinal motility
PP-526 SA01100 SANG-WON HONG Fucoidan Prevents DMN-Induced Liver Fibrosis In Rats
PP-527 SA01115 Xu Li Angiotensin II induces hepatocyte epithelial-mesenchymal-transition in vitro
PP-528 SA01155 Wu Qi-kai Effects of ZhengganHuayu Decoction on the Pathological Changes of Hepatic Fibrosis in Rats
PP-529 SA01158 Tran Bao Nghi REPRODUCIBILITY OF TRANSIENT ELASTOGRAPHY BY FIBROSCAN ACCORDING TO THE DEGREE OF LIVE FIBROSIS  IN CHRONIC LIVER DISEASES
PP-530 SA01298 Xin Zeng Identification of Anti-fibrogenic Components from Herbal Componds 861 In vitro and In vivo
PP-531 SA01317 Min Cong Antifibrotic Effects of Recombinant Adeno-Associated Viruses Carrying siRNAs Targeting Tissue Inhibitor of Metalloproteinase-1 on CCL4 Induced Liver Fibrosis in Rats
PP-532 SA01394 Tingbo Liang RAPAMYCIN INHIBITS LIVER FIBROSIS BY BLOCKING THE EPITHELIAL TO MENSENCHYMAL TRANSITION OF HEPATOCYTES
PP-533 SA01427 Wisuit  Pradidarcheep Activated Hepatic Stellate Cells in Thioacetamide –Induced Cirrhosis Express M3 Muscarinic Receptor
PP-534 SA01471 Jin Zixue NKT cells exacerbate liver fibrosis in hepatitis B virus transgenic mice
PP-535 SA01479 Chunqiu Hao Knockdown of CTGF by RNAi inhibits growth and activation of hepatic stellate cells and fibrosis of CCl4-cirrhotic liver
PP-536 SA01506 Jung Il Lee The Protective Effect of Resveratrol on Dimethylnitrosamine-induced Liver Fibrosis in Rats
PP-537 SA01535 Xuemei Li Effect of herbal ingredients formula（CGA）on the metabolism of collagen in DMN induced rat fibrotic liver
PP-538 SA01548 Subhadip Ghatak An insight into the anti-fibrotic efficacy of an Indian herb “Picrorhiza kurrooa”.
PP-539 SA01650 Chenghai Liu N-acetylcysteine effect on  CoCl2 intoxicated hepatic stellate cell line
PP-540 SA01694 Andrea Noetel Neuronal microRNAs targeting pluripotency factors like Lin-28 in myofibroblastic differentiation
PP-541 SA00441 Gamal Shiha Assessment of Hepatic Fibrosis by FibroScan Compared with Liver Biopsy in Chronic Hepatitis C Genotype 4
PP-542 SA00538 Yeon Seok Seo The results of Fibroscan is affected by the respiration
PP-543 SA01095 Gamal Shiha Assessment of Hepatic Fibrosis by FibroScan Compared with Liver Biopsy in Chronic Hepatitis C Genotype 4
PP-544 SA01371 Beom Kyung  Kim A liver stiffness measurement-based prediction model for liver cirrhosis, adjusting serum aminotransferase levels in hepatitis B patients
PP-545 SA01447 Chun Yeon Joo Non-invasive assessment of hepatic fibrosis by measuring the liver stiffness and biochemical markers in chronic liver disease
PP-546 SA01546 Ki Tae Yoon Liver stiffness measurement using acoustic radiation force impulse (ARFI) in chronic liver disease
PP-547 SA00044 Zou Meiyin The clinical significance of serum Vascular Endothelial Growth Factor (VEGF) and Model for End-stage Liver Disease (MELD) in patients with decompensated liver cirrhosis
PP-548 SA00090 Olav A Gressner Quality control accepted intraanalytical and interlaboratory variations lead to clinically relevant differences in calculated Fibrotest/ Actitest scores for the serum-based classification of liver fibrosis
PP-549 SA00128 Seung Ha Park The Usefulness of Multiple Biomarkers for the Prediction of Significant Fibrosis in Chronic Hepatitis B: A Critical Appraisal
PP-550 SA00417 Jun  Long Serum levels of adiponectin in patients with chronic hepatitis B virus infection are decreased and associated with hepatic fibrosis progression
PP-551 SA00643 Jian Zhang Applications of Transient elastography (FibroScan) for the assessment of liver fibrosis
PP-552 SA00677 Haijun Huang Metabolomic analysis of the feces reveals malabsorption in liver cirrhosis patients caused by Hepatitis B virus
PP-553 SA00767 R.T. Gao Serum Levels of TIMP-1 and TIMP-2 as Noninvasive Markers of Hepatic Fibrosis in Patients with Chronic Hepatitis B.
PP-554 SA00772 Chun-Lei  Fan Comparison of Transient Elastography (FibroScan) with FibroTest and APRI for the Prediction of Hepatitis B-Related Fibrosis
PP-555 SA00858 Raymond Kwok Diabetes Mellitus is associated with high liver stiffness measurements by Fibroscan®
PP-556 SA00862 Raymond Kwok A pilot study of Fibroscan®, Caffeine Breath test, APRI and AAR:  comparison of non-invasive markers of liver fibrosis in Chronic Hepatitis B patients.
PP-557 SA00979 Jun Ji Study on the association between GP73 and liver fibrosis
PP-558 SA01044 Feng Hui A preliminary clinical study on two kinds of ultrasonic elastographic technique for diagnosis of hepatic fibrosis
PP-559 SA01359 Pu-jun Gao The clinical significance of anti-beta2-GPI antibodies in the post-hepatitis B liver diseases 
PP-560 SA01570 Kausik Das Liver Stiffness Measure (LSM) in healthy subjects (HS) and in fatty liver or chronic hepatitis (CH).
PP-561 SA01711 Catalina Mihai Usefulness of real time elastography for the evaluation of liver fibrosis in chronic B and C viral hepatitis
PP-562 SA01825 Yusuf Yilmaz Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease
top
Poster Presentations: Portal Hypertension and Cirrhosis
Presentation No. Submission No. Presenting Author Title
PP-563 SA00141 Konstantinos Mimidis Eplerenone reverses spironolactone-induced painful gynaecomastia in patients with cirrhosis: a clinical study
PP-564 SA00293 Hong Joo Kim Endoscopic Treatment of Fundal Gastric Varices by Sclerotherapy with N-butyl-2-Cyanoacrylate
PP-565 SA00371 Hoda Abd el moety STUDY OF PORTAL AND SYSTEMIC LEVELS OF NITRIC OXIDE, ENDOTHELIN-1 AND PROCOLLAGEN III PEPTIDE IN CHRONIC LIVER DISEASE IN EGYPT
PP-566 SA00414 Byung Seok Kim Impact of antibiotic prophylaxis on reduction of serum nitric oxide and prevention of early rebleeding after endoscopic therapy in esophageal variceal hemorrhage: a prospective randomized controlled trial
PP-567 SA00460 Heon Ju Lee Does proton pump inhibitor increase the risk of spontaneous bacterial peritonitis in cirrhotic patients with ascites?
PP-568 SA00589 Moon Young  Kim The Effect of Angiotensin Receptor Blocker, Candesartan and Nonselective beta blocker, Propranolol Combination Therapy in Reduction of Portal Hypertension compared to Propranolol Montherapy
PP-569 SA00697 AKIKO MIYAMOTO BLOOD OXYGENATION IN RATS WITH COMMON BILE DUCT LIGATION BREATHING 100% OXYGEN
PP-570 SA01577 Guan Wee Wong Epidemiological and Clinico-biochemical Comparison between Hepatitis B and Alcoholic Liver Cirrhosis
PP-571 SA01658 Sang gyune Kim THE PARAMETERS OF DOPPLER ULTRASONOGRAPHY TO PREDICT GASTRIC VARICES IN PATIENTS WITH CIRRHOSIS 
PP-572 SA00070 Zheng Sheng Analysis of the risk factors of portal vein thrombosis in liver cirrhosis patients
PP-573 SA00325 Dae Won Jun The Correlation of Small Intestinal Bacterial Overgrowth, Orocecal Transit Time and Gastrointestinal Symptoms in Patients with Liver Cirrhosis
PP-574 SA00329 Luis Calzadilla Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease
PP-575 SA00359 Pises Pisespongsa Serum-ascites albumin concentration gradient (SAAG) greater than 20 g/L can be used as non-invasive indication for starting primary prophylaxis of esophageal variceal hemorrhage (EVH)
PP-576 SA00404 Fei LIU Prognostic evaluation of decompensated liver cirrhotic patients by means of MELD score combined with PA
PP-577 SA00435 Xiao Dinghong Effect of Fuzheng Huayu Capsule on Preventing Upper Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension: a Long-time Following-up
PP-578 SA00456 Lei Li The Analysis of the DNA fingerpring of intestinal flora in liver cirrhotic patients
PP-579 SA00516 Faouzi SALIBA MELD, MELD-Na, Child-Pugh and ICU Scores in Predicting Outcome of Cirrhotic Patients Admitted for an Acute Severe Decompensation: results of a recent cohort of 377 patients
PP-580 SA00534 Hamama-tul- Bushra Endoscopic Variceal Band Ligation in Chronic Liver Disease patients: experience at Holy Family Hospital, Rawalpnidi.
PP-581 SA00540 Muhammad Umar Liver Disease Related Mortality, A Review of 10 Year Audit
PP-582 SA00542 Muhammad Umar Upper GI Endoscopic Findings in Patients with Chronic Liver Disease
PP-583 SA00548 Tien Huey Lim Oral L-Ornithine-L-Aspartate is safe and effective in patients with intractable hepatic encephalopathy- the NZ Liver Transplant Unit experience
PP-584 SA00553 June Sung  Lee Incidenc and Risk Factor of Renal Failure Induced by Bacterial Infection other than Spontaneous Bacterial Peritonitis in Patients with Cirrhosis
PP-585 SA00629 Masroor Qazi PROGNOSTIC FACTORS OF MORTALITY IN PATIENTS WITH LIVER CIRRHOSIS (A TERTIARY CARE HOSPITAL EXPERIENCE)
PP-586 SA00683 Satoko  Uegaki Cystatin C-based assessment of renal function is more reliable compared to creatine-based assessment in cirrhotic patients
PP-587 SA00719 Sudhir Gupta Evaluation of Portal Hypertension in Children
PP-588 SA00722 Adrian Goldis FibroScan as a predictive tool for esophageal varices and variceal bleeding
PP-589 SA00768 Yun  Zhai Immunology foundation and clinical features of liver cirrhosis with bacterial infection
PP-590 SA00783 Naveen Kalra CORRELATION OF HVPG WITH CTP SCORE, MELD SCORE, SIZE OF VARICES, ASCITES AND ETIOLOGY IN CIRRHOTIC PATIENTS
PP-591 SA00876 Seul Ki Min The Comparative Results of Endoscopic Variceal Obliteration, Endoscopic Band Ligation, Balloon Occluded Retrograde Obliteration for Secondary Prophylaxis of Gastric Variceal Bleeding.
PP-592 SA00877 Hong XU The application of “U”retroflexion ligation therapy on esophagogastric varices(EGV1)
PP-593 SA00975 Feng Xing Effect of navel application with Chinese herbal cataplasm on patients with ascites due to liver cirrhosis
PP-594 SA00995 Tongyu Tang Prediction of esophageal varices in patients with cirrhosis
PP-595 SA01006 Kun-He ZHANG Risk factor survey and prediction model establishment for onset of esophageal varices bleeding
PP-596 SA01035 James Li Epidemiology of Patients with Liver Cirrhosis in a Single Tertiary Centre in Singapore
PP-597 SA01114 Moon Young  Kim Hepatogenous Diabetes Mellitus in Liver Cirrhosis: Relationship with Portal Pressure and Variceal Hemorrhage
PP-598 SA01123 Makoto Segawa The value of liver stiffness using FibroScan might be a predictive factor of the portal vein pressure.
PP-599 SA01128 Shuangsuo Dang Effects of marrow hemopoiesis factor TPO, CM-CSF on circumference blood corpuscle， in liver cirrhosis patients
PP-600 SA01131 Shuangsuo Dang Expression of CD34+ cell in bone marrow of cirrhosis patients
PP-601 SA01132 Shahid Ahmed Factors predicting the recurrence of spontaneous bacterial peritonitis in patients with cirrhosis
PP-602 SA01154 Zhengjie  Xu The influence of glucose metabolism disorders on complications of cirrhosis
PP-603 SA01159 Hoang Trong Thang The platelet count, the spleen diameter and the platelet count/spleen diameter ratio as a predictor of esophageal varices in cirrhosis
PP-604 SA01400 Karla Maria Nomorosa EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS IN REDUCING PORTAL PRESSURE IN CIRRHOTIC PATIENTS WITH PORTAL HYPERTENSION: THE ENRICH STUDY
PP-605 SA01481 Paulus  Kusnanto Non-Endoscopic Prediction of Esophageal Varices Grade in Patients with  Bleeding Liver Cirrhosis
PP-606 SA01568 Femmy Nurul Akbar Correlation between Degree of Cirrhosis by Child-Pugh Criteria and  Liver Stiffness in Liver Cirrhosis Patients
PP-607 SA01584 Ju Hee Seo Predictors of the development of refractory ascites in patients with hepatitis B virus-related cirrhosis experiencing the first episode of ascitic decompensation
PP-608 SA01611 ASHRAF ELFAKHRY Endoscopic Band Ligation Compared To Cyanoacrylate Injection For Management Of Gastric Varices: A Randomized Controlled Study
PP-609 SA01626 Zheng-jie Xu The influence of glucose metabolism disorders on complications of liver cirrhosis
PP-610 SA01705 Eric  Wee Endoscopic Assisted Insertion of the Sengstaken-Blakemore Tube in Uncontrollable Acute Esophageal Variceal Bleeding: A New and Novel Beside-The-Scope Method Under Direct Endoscopic Visualization.
PP-611 SA01717 Hosny Salama Efficacy  of  autologous  haematopoietic stem cells  transplantation in treating Egyptian patients with end-stage chronic liver diseases .
PP-612 SA01726 Adriano M Pellicelli Portal vein thrombosis in cirrhotic patients: safety and efficacy of low dosage of enoxaparin.
PP-613 SA01794 Tjahjadi Robert Tedjasaputra Hepatic Vein Flow Velocity Measurement Using Ultrasound Vascular Doppler as A Parameter of Severity of Liver Cirrhosis and Grading of Esophageal Variceal
PP-614 SA00058 Ehab Abdel-Khalek Circadian pattern of acute variceal bleeding in Egyptian patients
PP-615 SA00351 Junqi Niu Immunologic Characterization of Post-hepatitis Cirrhosis Caused by HBV and HCV Infection
PP-616 SA00430 Eiji Kakazu Branched-chain amino acids improve the maturation of dendritic cells in patients with advanced cirrhosis ex vivo.
PP-617 SA00453 Yun Zhai Octreotide decreases portal pressure: The Hepatic stellate cells may play a pivotal role
PP-618 SA00455 Lei Li The cardiac hemodynamics change in liver cirrhotic patients
PP-619 SA00766 Li-jun  Wang The production of hydrogen sulfide and its significance in hepatic stellate cells
PP-620 SA00790 Kun-He Zhang Interleukin-1A but not Interleukin-1B gene polymorphisms is associated with HBV-related hepatic cirrhosis
PP-621 SA00924 Dong-Hai YAN The association of polymorphisms of transforming growth factor-β1 with the susceptibility of HBV-related hepatic cirrhosis
PP-622 SA00932 Kun-He ZHNAG The gender difference in susceptibility of HBV-related cirrhosis is associated with polymorphisms of several genes
PP-623 SA00967 Kun-He ZHANG Gene polymorphisms of liver enzymes for toxin metabolism not associated with susceptibility of HBV-related hepatic cirrhosis
PP-624 SA01685 Ketut Mariadi Upper Gastrointestinal Bleeding was Associated With Higher IL-6 Level in Liver Cirrhosis
top
Poster Presentations: Cholelithiasis and Biliary Tract Disease
Presentation No. Submission No. Presenting Author Title
PP-625 SA00060 Ehab Abdel-Khalek Study of gall bladder contractility and prevalence of gallstones in Egyptian patients with liver cirrhosis
PP-626 SA00328 Max Petrov ENDOSCOPIC ULTRASONOGRAPHY OR RETROGRADE CHOLANGIOPANCREATOGRAPHY FOR SUSPECTED CHOLEDOCHOLITHIASIS?
PP-627 SA00662 Soung Hoon Cho Clinical significance of periampullary duodenal diverticula subtypes in choledocholithiasis patients
PP-628 SA00892 Zaigham Abbas Association of extra hepatic biliary atresia with cytomegalovirus infection
PP-629 SA01225 Oyuntsetseg Batkhuu Prevalence of cholelithiasis in patients with chronic viral hepatitis
PP-630 SA01306 Anand JALIHAL Endoscopic management of biliary disorders during pregnancy
PP-631 SA01657 Yong-xiang Zhu Prevalence of and risk factors for cholelithiasis in a general population of Shanghai, China
top
Poster Presentations: Acute Liver Failure
Presentation No. Submission No. Presenting Author Title
PP-632 SA00043 ZHANG Youyi Detection and significance of serum VEGF in patients with subacute-on-chronic liver failure
PP-633 SA00148 COSMAS RINALDI LESMANA Characteristics of Patients with Acute-on-Chronic Liver Failure (AoCLF) in Jakarta, Indonesia
PP-634 SA00249 Hao feng Xiong Acute liver failure in acute fatty liver of pregnancy : report of 12 cases
PP-635 SA00265 Canming He The protective effect of ethyl pyruvate on acute hepatic injury induced by D-galactosamine hydrochlorate in rats
PP-636 SA00275 Jian Zhou Catheter-related Infection in Artificial Liver Support System: Clinical Analysis of 698 Patients
PP-637 SA00295 Ming-Hua Zheng A novel model predicting mortality of the hospitalized patients with acute-on-chronic hepatitis B liver failure
PP-638 SA00354 Jian-Wu Yu The study of efficacy of lamivudine in patients with severe acute hepatitis B
PP-639 SA00362 Wei Li Plasma from patients with acute liver failure inhibit growth and proliferation of HepG2 cells and down-regulating the expressing of cyclin D1 and CDK4
PP-640 SA00381 C.L. Zhu Exogenous Administration of Hepatocyte Growth Factor Receptor by Gene Transfer Provides Protection against D-galactosamine/Lipopolysaccharide Induced Liver Failure
PP-641 SA00386 Sui Gao Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice
PP-642 SA00387 Tao Chen Increased killing of liver NK cells by Fas/FasL and NKG2D/NKG2DL contributes to hepatocyte necrosis in virus-induced liver failure
PP-643 SA00388 Tao Chen The novel KCTD9 contributes to immunologically mediated liver injury through NK cell activation in human and experimental severe viral hepatitis
PP-644 SA00415 Shi De Lin Different hepatitis B virus subgenotypes with high frequent precore/ core promoter mutation contribute to development of fluminant hepatitis during acute hepatitis B infection both in Japan and in China
PP-645 SA00419 AN Fangmei The Role of microRNA-122 Expression in Mice of Acute Liver Failure induced by D-GalN/LPS
PP-646 SA00438 Xinyan Li A simple scoring system to evaluate the severity of acute-on-chronic liver failure in Hepatitis B
PP-647 SA00505 Wei-jiang YE Clinical research of coupled plasma exchange filtration adsorption in the treatment of patients with chronic severe viral hepatitis B
PP-648 SA00601 Hai Li Leptin as a new predictor in HBV related acute on chronic liver failure
PP-649 SA00693 Kazuki Abe Inhibitory effect of glycyrrhizin on lipopolysaccharide and D-galactosamine-induced mouse liver injury
PP-650 SA00774 Ying Han The quantitive change of CD4＋CD25＋Regulatory T Cells and its clinical significance in liver failure infected with hepatitis B virus
PP-651 SA00964 Bo Feng A novel scoring system for prognostic prediction in d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure BALB/c mice
PP-652 SA00980 Pawan Rawal CLINICAL PROFILE OF ACUTE ON CHRONIC LIVER FAILURE IN CHILDREN AT A TERTIARY CARE CENTER IN NORTH INDIA
PP-653 SA01029 Liyang Wu Clinical observation in the treatment of HCV•RNA positive liver cirrhosis with small doses of interferon plus ribavirin
PP-654 SA01031 Wenfeng Ma Effects of ShengMaiSan on the levels of Lipolysaccharide and Cell Factors of Patients with Liver failure
PP-655 SA01059 Keiichi Fujiwara Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis
PP-656 SA01162 Fang Lin High frequency of Th17 cells is associated with worse prognosis of acute-on chronic-liver-failure caused by HBV infection
PP-657 SA01254 Vincent Lai Age & PT as prognostic factors of acute liver failure (16 years of national liver transplant program in Singapore)
PP-658 SA01417 Lin Bingliang A PROSPECTIVE COHORT STUDY ON ENTECAVIR TREATING PATIENTS WITH ACUTE ON CHRONIC HEPATITIS B LIVE FAILURE (ACHBLF)
PP-659 SA01533 Ning Li Altered Monocyte-derived Dendritic Cells Responses to poly (I:C) in Patients With Acute-on-Chronic Liver Failure
PP-660 SA01536 Kazuaki Inoue Prediction and early intensive medical care prevented development of fulminant hepatic failure and improved survival rate.
PP-661 SA01562 Xin Hou NKG2D–Rea 1 Recognition in a Novel Murine Natural Killer Cell–Dependent Fulminant Hepatitis
PP-662 SA01607 Monika Saxena Hepatoprotective activity of Rosa damascena against CCl4 induced damage in rats
PP-663 SA01636 Abhilasha Sharma Hepatoprotective effects of a proprietary herbal formulation (PHF) on acute liver injury in rats
PP-664 SA01645 Sangeeta Shukla Hepatoprotective effect of Rheum emodi on acute liver damage
PP-665 SA01701 Hitendra Garg Tenofovir reduces morbidity and mortality in patients with spontaneous reactivation of Hepatitis B presenting as acute-on-chronic liver failure (ACLF): A randomized placebo controlled trial
PP-666 SA01743 Jang Woo Shin CGX, Korean traditional medicine protects concanavaline A-induced acute liver injury
PP-667 SA01833 Jing-Hua Wang Hepatoprotective and Antioxidant effects of Ethyl Acetate Soluble Fraction of Amomum xanthoides
top
Poster Presentations: Hepatocellular Carcinoma
Presentation No. Submission No. Presenting Author Title
PP-668 SA01598 Fangfang Bu ASPP2 is a negative regulator of epithelial–mesenchymal transition and metastasis in HCC
PP-669 SA01617 Motohisa Tada Down-regulation of Suppressor of fused (Sufu) is implicated in the pathogenesis of human hepatocellular carcinoma.
PP-670 SA01623 Jian Zhao Epigenetic silence of ASPP1 and ASPP2 genes promotes tumor growth in HBV-positive hepatocellular carcinoma
PP-671 SA00050 Mengsen Li Alpha-fetoprotein inhibited the activity of PTEN caused retinoid-resistance of human hepatoma Cells
PP-672 SA00113 Zhizhen Dong Dynamic Expression of HIF-1α during the Development of Hepatocellular Carcinoma and Its Clinical Values
PP-673 SA00224 Mei-Li Chen Glutathione S-Transferase P1 (GSTP1) Gene Polymorphism Increases Age-Related Susceptibility to Hepatocellular Carcinoma
PP-674 SA00283 Judy Wai Ping Yam Caveolin-1 is overexpressed and promotes human hepatocellular carcinoma tumorigenesis via activation of HGF signaling
PP-675 SA00319 Yu-Yuan Li The roles of osteopontin in the invasiveness of hepatocellular carcinoma
PP-676 SA00436 Sen-Yung Hsieh Aberrant activation of ERBB3 in human hepatocellular carcinoma
PP-677 SA00611 Guangming Li Histone deacetylases (HDACs) and hepatocellular carcinoma (HCC)
PP-678 SA00631 Fanyin Meng MicroRNA-125b and hepatocellular carcinoma: the epigenetic association study and functional analysis
PP-679 SA00640 Xing Gu Four Polymorphisms Influence the HBV-Related HCC Susceptibility and Progression in Chinese Population
PP-680 SA00669 Heng-Hui ZHANG Foxp3 promoter demethylation controls Foxp3 gene expression in human hepatoma cell lines
PP-681 SA00670 Heng-Hui ZHANG The expression of Foxp3 in hepatocellular carcinoma cells inhibit anti-tumor immune response and contribute to the tumor cells migration and invasion
PP-682 SA00699 Ryosuke Muroyama Not HBx but fusion HBx translated from HBV integrant is implicated in the development and progression of hepatocellular carcinoma
PP-683 SA00720 Liang Teng Identification and Characterization of a Novel MicroRNA Involved In the Development of liver Cancer
PP-684 SA00781 Dae-Ghon Kim Altered BAMBI/TGF-beta-signaling by Hepatitis B Virus X protein in Hepatocellular Carcinoma
PP-685 SA00824 Angela M. Liu microRNA-375 targeting YAP signaling pathways in hepatocellular carcinoma
PP-686 SA00831 Jie Chen Association of CXCL10 G-201A polymorphism and the risk of HCC among Chinese cirrhotic CHB patients
PP-687 SA00874 Dean Tian The pro-apoptosis effect of p75NTR on human hepatocellular carcinoma cell line
PP-688 SA00923 Sarwat Fatima The Role of Dickkopf 4 (DKK4) on Wnt Signaling in Hepatocellular Carcinoma
PP-689 SA00925 Xiufeng Chu Functional analysis of FBX4 C80G polymorphism and splicing variants in Chinese HCC and ESCC patients
PP-690 SA00981 Suzhen Jiang Effects of Hepatitis B Virus S Promoter Deletion in Hepatoma Cell Lines in Vitro
PP-691 SA00985 A Singh Cyclooxygenase-2 (COX-2) Expression as a useful tool in the Prognosis of Progressing Liver Disease from Hepatitis to Hepatocellular Carcinoma (HCC)
PP-692 SA01011 Chi-Tan Hu An efficient direct tumor injection method in mice to induce intrahepatic metastasis
PP-693 SA01076 Qiang Chen Transcriptional coactivator AIB1 promotes human hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness
PP-694 SA01135 Lin Yang Small interfering RNA targeting hepatitis B virus X and 5-Aza-dC inhibit growth of hepatocellular carcinoma cells in vivo by reversing p16 hypermethylation and inducing p16 expression
PP-695 SA01215 Mengsen Li α-fetoprotein is a novel inhibitor of RAR-β for regulating the expression of CXCR4 in hepatoma cells
PP-696 SA01240 SATENDRA KUMAR NIRALA Tunneling Nanotubes: The Novel Conduit for Intercellular Communication and Promising Target for Anti-Cancer Therapies
PP-697 SA01245 Chaoqun Li Inhibition of Caspase-12 expression by silencing human androgen receptor expression in HepG2 cells
PP-698 SA01360 Pu-jun Gao A positive effect of beta2-GPI in the development of hepatocellular carcinoma
PP-699 SA01384 R.P Gao Expression and significance of connective tissue growth factor in human hepatocellular carcinoma
PP-700 SA01398 Tingbo Liang Rapamycin, a mTOR inhibitor, prevents hepatocellular carcinoma development in the DEN induce rat
PP-701 SA01452 Yongfeng Wang Aberrant miR-9-1 hypermethylation plays a role in HCC
PP-702 SA01693 Sandy Leung Kuen Au Frequent upregulation of Enhancer of Zeste Homolog 2 was implicated in Deleted in Liver Cancer 1 gene silencing and HCC progression
PP-703 SA01715 Dinesh Mani Tripathi ROLE OF Wnt/ β-CATENIN IN PROGRESSION OF ALCOHOLIC LIVER CIRRHOSIS AND RELATED HEPATOCELLULAR CARCINOMA
PP-704 SA01773 Natalia Pediconi TRANSCRIPTIONAL REGULATION OF miR-122
PP-705 SA00080 CHEN Nai-Ling Expressions and clinical significances of apoptosis proteins caspase 8, Bid, Bax, Cytochrome-c, caspase 9 and Bcl-2 in primary hepatic carcinoma
PP-706 SA00163 Zhang Peiyi Clinical study of relationship between expression of PTEN and ERK2 in hepatocellular Ccarcinoma.
PP-707 SA00934 Ming-Tzung Lin The diagnostic sensitivity of AASLD guideline on hepatocellular carcinoma and it’s application on non-cirrhotic patients
PP-708 SA00952 Hong Zang Expression of CAS in hepatocellular carcinoma tissues and its relationship with HBV infection
PP-709 SA01181 Hua Yang LAPTM4B-35 Combined with ASS as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Patients after Hepatectomy
PP-710 SA01286 Dong Qiong Zhu Upregulation of Osteopontin Encourages Tumor Growth and Metastasis of Human Hepatocellular Carcinoma
PP-711 SA01287 Zhang Xiao Fei PARs are not related to the effect that thrombin mediates overall survival and recurrence of HCC patient who underwent primary and curative resection
PP-712 SA01499 Zhu Wen Wei The Functional Role of Metastasis-Favoring Gene GOLM-1 in Heptocelluar Carcinoma
PP-713 SA01504 Do Young Kim Kim Can combined measurement of AFP and PIVKA-II improve the performance of HCC surveillance? - A prospective randomized study
PP-714 SA01664 Myeong Jun Song Usefulness of prediction of treatment response by 18F-FDG PET for Hepatocellular carcinoma
PP-715 Offline 1 Balkrishan Sharma Comparison of 7 staging systems in North Indian cohort of Hepatocellular Carcinoma
PP-716 SA00211 Zakia Abdelrahman Evaluation of Hepatocyte Growth Factor (HGF) and Interlukin-1 beta (IL-1β) in Patients with Hepatitis C virus infection (HCV) and Hepatocellular Carcinoma (HCC)
PP-717 SA00389 Jyotdeep Kaur Role of promoter region methylation of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in India
PP-718 SA00469 Seong Woo Nam Efficacy of Tumor markers for early detection of metastasis in patients with hepatocellular carcinoma
PP-719 SA00552 Mitsuaki Sato Judgement of biological malingnant potential by combination diagnosis of Gd-EOB-DTPA MRI and Sonazoid-contrast enchanced ultrasonography in hepatocellular carcinoma
PP-720 SA00752 Peng Li Evaluation of diagnostic value of sera AFP for primary hepatocellular carcinoma
PP-721 SA00775 Ali Nada AFPL3% Versus AFP in diagnosis of HCC in Egyptian patients
PP-722 SA00822 Yunpeng Zhao Assessment of serum N-glycans marker in HBV-related hepatocellular carcinoma follow-up study
PP-723 SA01110 A.Kadir Dokmeci Diagnostic value of Lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for Hepatocellular Carcinoma (HCC): First study with a Turkish patient cohort
PP-724 SA01140 Shintaro Kikkawa Early diagnosis of hepatocellular carcinoma using the new generation of high-sensitve lens culinaris agglutinin-reactive fraction of alpha-fetoprotein assay
PP-725 SA01216 Sirong Chen Bone as the First Site of Metastasis from Hepatocellular Carcinoma – Detection and Analysis by Dual-Tracer PET/CT
PP-726 SA01295 Dai Chun Oct4, an embryonic stem cell marker, promoting cell proliferation and metastasis is an oncogene in Hepatocelluar carcinoma
PP-727 SA01603 Rongxin Chen Osteopontin, a single marker for predicting the prognosis of patients with the tumor-node-metastasis (TNM) stage I hepatocellular carcinoma after surgical resection
PP-728 SA01672 Zhen Zeng Up-regulation of PD-1/PD-L1 in peripheral blood mononuclear cells predicts poor prognosis in HBV-related hepatocellular carcinoma patients
PP-729 SA01811 Qing Wang Detection of the altered expression of DDAH-1 in hepatocellular carcinoma by using laser capture microdissection and proteome analysis
PP-730 SA01214 Jun-liang Fu Increased FoxP3+ regulatory T cells are associated with tumor metastasis and poor survival in hepatocellular carcinoma patients
PP-731 SA01258 Zhi Du Association of the single nucleotide polymorphism of IL-10 and ALDH2 with hepatocellular carcinoma
PP-732 SA01551 Ha Na Park Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience in Korea
PP-733 Offline 2 Balkrishan Sharma Changing etiology of hepatocellular carcinoma in North Indian HCC patients
PP-734 SA00119 Takamasa Ohki Metabolic syndrome is an independent risk factor of hepatocellular carcinoma recurrence after curative treatment in non-B non-C chronic liver disease patients
PP-735 SA00256 Nalani Grace Family history does not affect survival from hepatocellular carcinoma
PP-736 SA00446 Fen Jiang MD PHD African-American Ethnicity, Filipino Ethnicity, and Low SES are Independent Unfavorable Prognostic Factors for Overall Survival in Hepatocellular Cancer
PP-737 SA00646 Xiangmei Chen Association of TNF-a gene polymorphisms with risk of hepatitis B-related hepatocellular carcinoma in Chinese population
PP-738 SA01106 A.Kadir Dokmeci Characteristics of hepatocelluler carcinoma in Turkey
PP-739 SA01197 Feng Shi PD-1 and PD-L1 upregulation promotes tumor evasion of immune control in hepatocellular carcinoma patients
PP-740 SA01304 Hong-Xing Wu Hepatocellular Carcinoma Mortality in Canada from 1980 to 2004
PP-741 SA01436 SHYAM KOTTILIL Screening for HCC in India: Early Detection and Impact on Survival.
PP-742 SA01630 Suwandhi Widjaja Changing of HCC profile in the last decade at Medistra Hospital
PP-743 SA00621 Guohong Han Transarterial chemoembolization in combination with sorafenib for advanced hepatocellular carcinoma in hepatitis B–endemic Asian population
PP-744 SA00708 Sung Bum Cho Comparsion of sorafenib and radiotherapy in unresectable hepatocellular carcinoma patients whom transcatheter arterial chemoembolization was ineffective or unsuitable
PP-745 SA00757 Gerby Coronel Transarterial Chemoembolization for hepatocellular carcinoma: Long term outcome and Prognostic factors affecting survival
PP-746 SA00794 Jeong-Hoon Lee Transarterial chemoembolization significantly improves the overall survival in patients with hepatocellular carcinoma invading main portal vein
PP-747 SA00832 Esperanza Grace Santi Major Complications of Percutaneous Radiofrequency Ablation (RFA) are Associated with the Number of RFA Zones Created: A Caution on Trying to Do Too Much
PP-748 SA00891 Ming Kuang Ethanol Ablation Of Hepatocellular Carcinoma Sized Up To 5 cm By Using A Multi-pronged Injection Needle With High-Dose Strategy
PP-749 SA00905 Soon Sun Kim Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Treatment of Single Hepatocellular Carcinoma Smaller Than 4 cm
PP-750 SA01020 Zhen-Wei Peng A Prospective Study on Radiofrequency Ablation Versus Surgical Resection for Small Solitary Hepatocellular Carcinoma
PP-751 SA01204 Teh-Ia Huo Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency
PP-752 SA01266 Kyung In Lee The Comparison of Treatment Efficacy Between Concurrent Chemoradiotherapy and Hepatic Arterial Infusion Therapy in Advanced Hepatocellular Carcinoma
PP-753 SA01606 Sehun Kang Comparing the outcomes of transarterial chemoembolization and hepatic resection in patients with single hepatocellular carcinoma less than 3 cm
PP-754 SA00526 Kazuhiro Kasai Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion
PP-755 SA00660 Won Hyeok Choe Sorafenib combined with transarterial-chemoembolization for unresectable hepatocellular carcinoma: Focusing on side-effects during early-phases of treatment
PP-756 SA00872 Seul Ki Min The Comparison of Effects between Concurrent Chemoradiation Therapy and Hepatic Arterial Infusion Chemotherapy using 5-fluorouracil, cisplatin and doxorubicin for Unresectable Hepatocellular Carcinoma
PP-757 SA00343 Fumihiko Kanai Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase inhibitor, TSU-68, in the phase I/II study for advanced hepatocellular carcinoma
PP-758 SA00776 Yuqin Li Immunological Effects of a Recombinant Genetic Vaccine Encoding Hepatocellular Carcinoma (HCC) Antigen HCA661 and Mycobacterium Tuberculosis heat shock protein 70 C-terminal stimulatory domain fusion protein
PP-759 SA01024 Shuntaro Obi Combination therapy of intra-arterial 5-FU and systemic IFN for advanced hepatocellular carcinoma with portal venous invasion.
PP-760 SA01510 Wei Zhang Effects of avastin combined with sorafenib in a highly metastatic murine model of human hepatocellular carcinoma
PP-761 SA01565 Christian Freise L.obtusiloba exerts anti-mitogenic effects and decreases expression of pro-angiogenic HIF-1α and tumor-elevated PPARγ and COX-2 in human hepatocellular carcinoma cell lines
PP-762 SA01575 Rajan Somasundaram Intermediate conductance calcium-activated potassium channel (IKCa) as target for anti-neoplastic treatments: specific IKCa blocker TRAM-34 in HCC blocks in vitro invasion and migration
PP-763 SA01601 Su Cheol Park Silibinin enhances the growth inhibitory effects of gefitinib in hepatocellular carcinoma
PP-764 SA01649 Xiao-Dong Zhu Evaluating antiangiogenic effects of pazopanib (GW786034B) in hepatocellular carcinoma xenograft models by quantitative contrast-enhanced ultrasonography
PP-765 SA00531 Naruhiko Nagata Two years of TAE experience in Tokai University hospital
PP-766 SA00566 Paolo Villareal Radiofrequency Ablation Combined with Hypertonic Saline: An Ex Vivo Study in Bovine Liver
PP-767 SA00614 Nam Hwan Park A Case of Complete Response After Transaterial Chemoembolization and Radiotherapy for Portal Vein Malignant Thrombus in Patient With Unresectable Hepatocellular Carcinoma
PP-768 SA00615 Alexander Kabakov Hsp27 phosphorylation can enhance radioresistance of hepatocarcinoma cells by stimulating Akt activation
PP-769 SA01610 Chinburen Jigjidsuren Introduction of RFA in Mongolia: year 1 treatment results at National Cancer Center of Mongolia.
PP-770 SA00528 Noriyuki Oba Hepatic Resection for Hepatocellular Carcinoma with an Involvement  of Inferior Vena Cava
PP-771 SA01609 Woo Young Shin Hepatic resection for hepatocellular carcinoma with portal vein invasion
PP-772 SA01679 Jeong Won Jang Effect of hepatitis B viral status on cancer recurrence and long-term prognosis after surgical resection in patients with hepatocellular carcinoma
PP-773 SA00157 Markiyan Soloviy LAPAROSCOPIC VERSUS OPEN HEPATECTOMY – A META-ANALYSIS.
PP-774 SA00192 Joji Yamamoto Anterior approach for a huge hepatocellular carcinoma
PP-775 SA00305 Chien-Wei Su Minimal Fibrosis and Lower Aspartate Aminotransferase-Platelet Ratio Index Is Associated With Better Prognosis for Patients With Small Solitary Hepatitis-B Virus related Hepatocellular Carcinoma Underwent Resection Surgery
PP-776 SA00593 Byung Seok Lee A Case of Ruptured Hepatocellular Carcinoma, Treated by Two Staged Operation
PP-777 SA00714 Chinburen Jigjidsuren Surgical Treatment Outcomes for Liver Cancer Patients at the National Cancer Center (NCC) of Mongolia
PP-778 SA00779 Thomas Decaens AFP level is a simple test for a reasonable expansion of Milan criteria for liver transplantation for hepatocellular carcinoma
PP-779 SA01010 Tian Yang Viral load is associated with long-term survival after curative resection of hepatitis B virus-related hepatocellular carcinoma: a prospective cohort study
PP-780 SA01305 Hong-Guang Wang Robotic-Assisted Laparoscopic Anatomic Hepatectomy in China: Initial Experience
PP-781 SA01593 Woo Young Shin Prognostic role of preoperative radiologic morphology of huge (≥10cm) hepatocellular carcinoma
PP-782 SA01596 Kyung-Suk Suh RECENT IMPROVEMENT OF OUTCOME OF HEPATIC RESECTION FOR HEPATOCELLULAR CARCINOMA
PP-783 SA00155 Eun Ju Cho Protein disulfide isomerase inhibition potentiates hexokinase II inhibitor-induced hepatocellular carcinoma cell death by augmenting ER stress
PP-784 SA01673 Tae Hyo Kim Clinical characteristics of hepatocellular carcinoma developed in the patients with chronic hepatitis B undergoing antiviral therapy
PP-785 SA00129 Ayesha Baig LEVEL OF ALPHA-FETPPROTEIN IN DIABETIC PATEINT HAVING HEPATOCELLULAR CARCINOMA
PP-786 SA00666 Su Jong Yu Hepatocellular Carcinoma with Bile Duct Invasion: Survival and Prognostic Factors in Inoperable Cases
PP-787 SA00871 Jae Young Jang The analysis of variceal hemorrhage in the patients with hepatocelluar carcinoma
PP-788 SA01060 Zaigham Abbas Hepatocellular carcinoma in HDV: Does it differ from HBV monoinfection
PP-789 SA01108 A.Kadir Dokmeci Comparison of therapeutic effects between percutaneous ethanol injection therapy and radiofrequency ablation for hepatocellular carcinoma
PP-790 SA01137 Yunhong Xia Inhibition of T-Cell Responses by Intratumoral Hepatic Stellate Cells Contribute to Migration and Invasion of Hepatocellular Carcinoma
PP-791 SA01219 Sirong Chen Characteristics of Bone Metastasis as the Only Site of Metastasis are Different from Those of Being Part of Multi-Organ Metastases in Hepatocellular Carcinoma
PP-792 SA01236 Young Eun Chon Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: Endoscopic findings and risk factors
PP-793 SA01361 Pu-jun Gao Beta2-GPI: a possible factor in the development of hepatocellular carcinoma
PP-794 SA01422 Xiaoyan Xie Ablation Therapy with Real-Time Virtual System for Treating Malignant Liver Tumo
PP-795 SA01455 Yun  Deng Epigenetic silencing of WIF-1 in hepatocellular carcinomas
PP-796 SA01465 Carmen W.H. Chan The effects of palliative treatment modalities of Hepatocellular Carcinoma (HCC) on Patients' quality of life
PP-797 SA01695 Izumi Kirino Management of Spontaneously Ruptured Hepatocellular carcinoma: 15-year Experience in a single institution.
PP-798 SA01783 Cong Wen-Ming* Small hepatocellular carcinoma of 3 cm or less in diameter is a predictor of biological behavior
top
Poster Presentations: Imaging Modalities
Presentation No. Submission No. Presenting Author Title
PP-799 SA00517 Yusuke Shinozaki Spatial Accuracy Experience of Ultrasound Volume Data in Newly Developed in DICOM Formatting System and Experimentation
PP-800 SA01503 JOTA WATANABE Usefulness of intraoperative fluorescence imaging using indocyanine green to evaluate local anatomy in hepatobiliary surgery
top
Poster Presentations: Cholangioca and Other Liver Neoplasm
Presentation No. Submission No. Presenting Author Title
PP-801 SA01434 Yukihiro Koike The Earlier Introduction of Radio-Fequency Ablation, the Better may be Prognosis of the Patients with Unresectable Liver Metastases of Colo-Rectal Cancer.
PP-802 SA01437 Tenyu Motoyama Intra-arterial 5-Fluorouracil and Interferon Combination Therapy of for Advanced Cholangiocellular Carcinoma.
PP-803 SA00586 Zhang Qin The diagnosis and clinical significance of primary non-Hodgkin lymphoma of liver by needle biopsy
PP-804 SA00904 Jun Yong Bae The characteristics of focal nodular hyperplasia on abdominal images; case series and single center experience
PP-805 SA01015 Hiroshi Yoshida Infected hepatic cyst treated with percutaneous transhepatic drainage
PP-806 SA01220 Sirong Chen A Case Report of Hepatic Angiomyolipoma with Unusual Presentation: Significance of 11C-Acetate PET/CT
PP-807 SA01376 Karla Maria Nomorosa Primary Carcioid Tumor of the Liver in a Young Filipino Female
top
Poster Presentations: Liver Transplantation
Presentation No. Submission No. Presenting Author Title
PP-808 SA00451 Man Ki Ju The effect of different techniques for bile duct dissection on post-transplant biliary complication in living donor liver transplantation
PP-809 SA00690 Joon Suk Kim The Effect of Pretransplantation Lamivudine Resistance on the Prognosis in Liver Transplantation Recipients
PP-810 SA01632 Nam-Joon Yi IMMUNOHISTOCHEMICAL DETECTION OF MRP2 AS AN EARLY POSTOPERATIVE MARKER FOR PREDICTION OF PERSISTENT BILIARY STRICTURE AFTER LIVER TRANSPLANTATION
PP-811 SA01737 Gi-Young Ko Long-term efficacy of stent placement for treating inferior vena cava stenosis following liver transplantation
PP-812 SA00093 Zhipeng Sun Injury and expression of redox factor-1 and ICOS in early and late period after liver transplantation of rats model
PP-813 SA00140 Petru MATUSZ Morphological particularities with surgical significance of the venous drainage of the caudate lobe
PP-814 SA00143 Petru MATUSZ Intrahepatic portal system with multiple anatomical variants. Study on corrosion casts
PP-815 SA00144 Petru MATUSZ Middle hepatic vein. Morphological considerations with surgical value
PP-816 SA00320 Hong-Li SONG Effects of methylprednisolone on the expression of integrin alpha 5 beta1 and cyclin A in HepG2.2.15 cell line
PP-817 SA00384 Ed Gane Liver Transplantation for Hepatitis B is Associated with Excellent Graft and Patient Survival
PP-818 SA00626 Haoyuan Wang Coagulation Variations of the Patients with Local Advanced Liver Cancer Undergoing Liver Transplantation
PP-819 SA00656 Yue Shi Postoperative Infection im Patients with Hepatoma undergoing Liver Transplantation
PP-820 SA00873 Maggie Ow Tobacco Smoking and Long-Term Outcome in Liver Transplantation
PP-821 SA00879 Wang zheng Xin The Relationship Between The ATP Within CD4+T Lymphocyte And The Acute Rejection After Liver Transplantation
PP-822 SA01146 Bo Li Hypophosphatemia may not correlated with hepatic regeneration after living donor hepatectomy
PP-823 SA01148 Emilia Prakoso Ductular reaction in hepatitis C recurrence post liver transplantation.
PP-824 SA01247 See Ching Chan Flowmetry and Manometry Guided Graft Vascular Inflow Modulation Scheme in Liver Transplantation
PP-825 SA01290 Ji Chun Zhao Consecutive 124 cases without hepatic arterial thrombosis after adult-to-adult living donor liver transplantation (ALDLT) in single center from west China
PP-826 SA01432 Bhupender Singh First Successful Split and Auxiliary Partial orthoptic liver transplant in India-A case report
PP-827 SA01518 Ying Wu Donor Diabetes Mellitus Type II Predicts Graft Survival In Hepatitis C Positive And Hepatitis C Negative Liver Transplant Recipients.
PP-828 SA01537 Rachel Rui Qi Yu Assigning MELD score for Hepatocellular Carcinoma for Patients on Waiting List in a Singapore Liver Transplant Center
PP-829 SA01573 Yang Won Nah Graft versus Host Disease following Liver Transplantation
PP-830 SA01647 Jun Fan COMPARISION OF QUANTITATIVE REAL-TIME PCR WITH PP65 ANTIGENEMIA ASSAY FOR MESURING VIRAL LOAD OF CYTOMEGALOVIRUS (CMV) IN TRANSPLANT RECIPIENTS
PP-831 SA01653 Taiji Tohyama Two rare recurrences of hepatocellular carcinoma within the Milan criteria after living donor liver transplantation
PP-832 SA01675 Xuan Zhang Study of HCMV infection in recipients of liver transplantation or bone marrow transplantation
PP-833 SA01725 W Ray Kim MELD score and risk of mortality in liver transplant candidates with hepatitis B cirrhosis: A lesson from the US experience
PP-834 SA01784 Cong Wen-Ming Pathological diagnosis of 1052 liver biopsies after liver transplantation: a single center experience
top
Poster Presentations: Molecular and Cellular Biology
Presentation No. Submission No. Presenting Author Title
PP-835 SA00109 Yosuke Osawa Role of Kupffer cells in cholestatic liver injury in mice
PP-836 SA00057 Zhan Xuejun The Morphological Observation on the Induction of Apoptosis of Human Hepati Carcinoma Cells by Herbal Medicinal Mixture-Containing Serum
PP-837 SA00181 Hui Yang Histone Modification-mediated CYP2E1 Gene Expression and Apoptosis of HepG2 Cells
PP-838 SA00284 Man Li The study of the expressions of some immune effector molecules in CD4+T lymphocytes from CHB-infected patients
PP-839 SA00286 Xiao-jun Zhu The characteristics of the expressions of immune effector molecules in CD8+T lymphocytes from patients infected with chronic hepatitis B
PP-840 SA00289 Man Li The study of the expressions of immune effector molecules in NK cells from CHB-infected patients
PP-841 SA00549 Xiuchuan Yan Screening for Active Compound of Danshen on Inhibiting Hepatocyte Apoptosis
PP-842 SA00585 Xin Ji TGFβ1 gene codon10 SNP influences secretion and function of hepatic cells
PP-843 SA00739 Li-Teh Liu Enhancement of Chemotherapeutic Drug Toxicity on Human Hepatocellular Carcinoma Cells In Vitro by Vitamin K2
PP-844 SA00751 Yumin Xu Mechanisms of Cytoprotective Effects of Grape on Liver Cells
PP-845 SA00809 Xuewu Zhang Inhibition of 5, 2´, 4´-trihydroxy-6，7，5´-trimethoxyflavone on proliferarion of hepatoma HepG-2 cell line
PP-846 SA01134 Lin Yang Wild and mutant Hepatitis B virus X protein with deletion at COOH-terminus induce cell cycle progression via down-regulating p16 and RB pathway in HepG2 cells
PP-847 SA01519 Yangxi Li CRACC expression of murine hepatic lymphocytes after Poly (I:C) treatment
PP-848 SA01534 Yonglin Chen Contribution of Liver Blood Supply to the Predominant Content of NK Cells in Liver
PP-849 SA01542 Hui Peng A distinct subset of murine natural killer cells in liver and mesenteric lymph nodes
PP-850 SA01571 Meijuan Zheng The trafficking of hepatic NK cells to liver draining lymph nodes
PP-851 SA01583 Xiaojun Jiang Identification and Characterization of Immature NK cells in bone marrow and liver
PP-852 SA01714 Kewei Wang Glycochenodeoxycholate-Induced Hepatocyte Apoptosis: Signalling Pathway Activated by Survivin and Nuclear Factor-kappaB
PP-853 SA01625 Sung Hoon Choi Effects of the inhibition of hypoxia-inducible factor-1α (HIF-1α) and interleukin 8 (IL-8) on angiogenesis and metastasis in liver cancer in vitro
PP-854 SA00248 Lei Li The shRNA Expression Retroviral Vector can Prolong It’s Anti-HBV Effect in Mice Versus Nonviral Vector without Viral Package Process
PP-855 SA00261 Luwen Wang Expression of APOBEC3G induced by interferon-alpha in HepG2 2.2.15 cells
PP-856 SA00263 Hui Chen Effects of APOBEC3G gene on biological behaviors of HepG2 2.2.15 cells
PP-857 SA00412 PAN Yun-Feng Epidemiologic study on plasmid-mediated high-Level resistance to aminoglycosides in Acinetobacter baumannii isolates of Zhejiang due to 16S rRNA methylation
PP-858 SA00479 Yue-Feng Chen Relationship between polymorphism of epidermal growth factor 5’UTR variant G61A gene and cirrhosis in Chinese patients
PP-859 SA00604 Peng Qi A variant in microRNA-196a2 is not associated with susceptibility and progression of hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection
PP-860 SA01176 William Davigdor Identification of miRNA Expression Profiles Differentiating Hepatitis C Genotype 1 and 3 liver Injury
PP-861 SA01508 Mei Huang Construction of a liver-specific shRNA vector for simultaneously silencing multiple NKG2D ligands
PP-862 SA00909 Cuiping Xu Exogenous Noggin affect liver regeneration after partial hepatectomy in rats
PP-863 SA01473 Rui Sun Natural killer cells are involved in impairment of murine liver regeneration via tumor necrosis factor-α after carbon tetrachloride treatment
PP-864 SA01543 Ziping Qi Immunological Injury of Fah-deficient Mice after NTBC Withdrawn
PP-865 SA01618 Yuxiang Li The effects of human hepatocyte growth factor gene on CCL4 injured human hepatocyte and rat hepatic stellate cell line and its mechanism
PP-866 SA00101 Ying Zhang The effect of canonical Wnt signaling pathway on the proliferation and differentiation of rat hepatic oval cell
PP-867 SA00200 Chan Xie Asialoglycoprotein receptor was important for human bone marrow mesenchymal stem cells resistant to HBV infection
PP-868 SA00597 Yoshihiko Tsukada Extracellular matrix is required for the survival and differentiation of transplanted hepatic progenitor cells
PP-869 SA01077 Qiuwei Pan Mobilization of hepatic mesenchymal and hematopoietic stem cells from adult human liver grafts
PP-870 SA01221 Liang Peng Comparative Study of Hepatocyte-like Cells differentiated from Mesenchymal Stem Cells of Hepatitis B Patients with Liver Failure
PP-871 SA01405 Wang Chunguang The significance on NF-kB changes for HGF-mediated proliferation and differentiation in human fetal hepatic stem cells.
PP-872 SA01544 Aiting Yang Differential Effects of Connective Tissue Growth Factor and Transforming Growth Factor-β on Rat Hepatic Progenitor Cells
PP-873 SA01567 Xian Wu The phenotypes of mouse nature killer cells in liver and spleen of different ages
PP-874 SA01615 Jun Fan Cytomegalovirus gBn Genotypes in Chinese Hematopoietic Stem Cell Transplant Recipients
PP-875 SA01758 Azita Hekmatdoost Hepatocyte-like Cell Clusters Derived from human Menstrual Blood-derived stem cells.
top
Poster Presentations: Miscellaneous
Presentation No. Submission No. Presenting Author Title
PP-876 SA00316 Gao Hainv The clinical significance of C-Reactive Protein (CRP) in determining the end point of pyogenic liver abscess treatment
PP-877 SA00323 Rakesh Mittal Tubercular liver abscesses
PP-878 SA00368 Soad Zaki Histocompatibility Antigens In Relation To Hepatic Schistosomiasis
PP-879 SA00410 Manal El-Hamamsy A pilot Study of the Effect of Desferrioxamine as Supplement to
PP-880 SA00413 Osama Karamalla Prevalence of Hepatitis B among patients of renal problems (Hepatitis-B associated nephropathy) in selected hospitals in Khartoum State between September and November 2007. Sudan
PP-881 SA00628 Qingyu Zhao PPC Protects Liver Function and Ameliorates Endotoxic Shock via Inhibition of Acute Infalmmatory Responses
PP-882 SA00731 Vincenzo Morabito Early management of endotoxemia using the endotoxin activity assay and Polymyxin-B based hemoperfusion
PP-883 SA00746 Chi-Tan Hu Co-axial liver biopsy is the solution for hepatologists to obtain adequate tissue for molecular studies
PP-884 SA01016 Hiroshi Yoshida Placement of a percutaneous transhepatic biliary stent using a silicon drain with channels along the sides for the treatment of a stenotic hepaticojejunostomy
PP-885 SA01152 Hoang Trong Thang EVALUATION THE CONCENTRATION OF TNF ALPHA IN DIAGNOSIS AND PROGNOSIS OF ACUTE PANCREATITIS
PP-886 SA01198 Saravana Kumar Karunanathy PRE HEPATIC AND POST HEPATIC PORTAL HYPERTENSION: HOSPITAL SELAYANG EXPERIENCE
PP-887 SA01487 Ming-Lung Yu Association between metabolic syndrome and chronic hepatitis B in Taiwan: a community-based study
PP-888 SA01604 Sonia Johri Combined administration of DPA and Selenium reverses beryllium induced hepatic dysfunction
PP-889 SA01613 Jacobus A Auwyang Oral Glucose Tolerance (OGT) in Liver Cirrhosis
PP-890 SA01687 Jun Fan The initial screening of epitope in HCMV gB
PP-891 SA01806 Fumiki Kushihata Bleeding control in the laparoscopic partial liver resection special reference to clinicopathological examination about RFA precoagulation
PP-892 SA01827 Sabahattin Kaymakoglu IS THERE A BENEFIT OF ANTICOAGULANT THERAPY IN THE SURVIVAL OF
top

 

 

Key Dates

Conference Secretariat (International)

Conference Secretariat (China)

Abstract Submission System Open:

10 August, 2009

Abstract Submission Deadline:

30 November, 2009

Acceptance Notification:

18 December, 2009

Early Registration Deadline:

4 January, 2010

Pre-registration Deadline:

7 March, 2010

APASL 2010 BEIJING:

25 - 28 March, 2010

9/F, New Hennessy Tower,
263 Hennessy Road, Wan Chai,
Hong Kong
Tel: +852-2827-2090
Fax: +852-2827-2220
Email: info@apasl2010beijing.org

U-Link Business Solutions Co., Ltd.
Room 510, B Tower, Free Town Center, No. 58 Dongsanhuan Road, Chaoyang District, Beijing, China 100022
Tel: +86 10 5867 2121 ext 829
Fax: +86 10 5867 4337
Email: info@apasl2010beijing.org

 

© 20th Conference of the APASL, 2010, Beijing. All rights reserved.